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The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of rapidly spreading 
illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent 
guidance to clinicians caring for the sickest group of these patients is needed. 
Methods 
We formed a panel of 36 experts from 12 countries; all panel members completed the World Health 
Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the 
management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the 
management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic 
reviews on most questions on supportive care. We assessed the certainty in the evidence using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations 
based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. 
Recommendations were either strong or weak, or in the form of best practice recommendations.  
Results 
The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which 4 are best practice 
statements, 9 are strong recommendations, 35 are weak recommendations, and no recommendation was 
provided for 6 questions. The topics were: 1) infection control, 2) laboratory diagnosis and specimens, 3) 
hemodynamic support, 4) ventilatory support, and 5) COVID-19 therapy.  
Conclusion 
The Surviving Sepsis Campaign COVID-19 panel, issued several recommendations to help support 
healthcare workers caring for critically ill ICU patients with COVID-19. A living guideline model will be 





At the end of 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
resulted in an acute respiratory illness epidemic in Wuhan, China [1]. The World Health Organization (WHO) 
termed this illness Coronavirus Disease 2019 (COVID-19). 
By the time this guideline panel was assembled, the COVID-19 became a pandemic and had affected over 
120,000 individuals in more than 80 countries, and resulted in more than 5000 deaths worldwide [2].   
The WHO and the United States Center for Disease Control (CDC) and Prevention have issued preliminary 
guidance on infection control, screening and diagnosis in the general population, but there is limited guidance 
on the acute management of critically ill patients with severe illness due to COVID-19. 
 
Guidelines Scope 
This guideline provides recommendations to support hospital clinicians managing critically ill adults with 
COVID-19 in the intensive care unit (ICU). The target users of this guideline are frontline clinicians, allied 
health professionals, and policymakers involved in the care of patients with COVID-19 in the ICU. The 
guideline applies to both high and low-middle income settings. 
 
Guideline Teams and Structure 
The Surviving Sepsis Campaign (SSC) COVID-19 subcommittee selected panel members based upon a 
balance of topic expertise, geographic and gender balance, as much as possible.  
 
The SSC COVID-19 panel was assembled and worked within very tight timelines in order to issue 
recommendations in a timely manner.  The panel included experts in guideline development, infection 
control, infectious diseases and microbiology, critical care, emergency medicine, nursing, and public health.  
The panel was divided into four groups: 1) infection control and testing, 2) hemodynamic support, 3) 
ventilatory support, and 4) therapy.  
The Guidelines in Intensive Care Development and Evaluation (GUIDE) group provided methods support 
throughout the guideline development process. 
 
Management of Conflict of Interests 
All panel members completed a conflict of interests (COI) form prior to joining the guideline panel [3, 4]. We 
used the GRADEpro guideline development tool (GDT) online software 
(http://gdt.guidelinedevelopment.org) to administer WHO COI disclosure forms to participating panel 
members. Direct financial and industry-related COIs were not permitted and were considered disqualifying. 
The development of this guideline did not include any industry input, funding, or financial or non-financial 
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contribution. No member of the guideline panel received honoraria or remuneration for any role in the 
guidelines process.  
 
Methods 
The guideline development process is summarized in Figure 1. All actionable guideline questions were 
structured in the Population, Intervention, Control, and Outcome(s) (PICO) format, with explicit definitions, 
whereas descriptive questions were not. 
Content and methods experts in each group participated in developing the guideline questions. The PICO 
format provided the basis of inclusion and exclusion criteria for the literature search (when done) and 
identification of relevant studies. 
To facilitate rapid development of recommendations, we did not perform a novel systematic prioritization of 
outcomes, but used the outcome prioritization informed by the ongoing SSC guideline 2020 work and expert 
input [5]. Accordingly, we focused on hospital mortality and serious adverse events outcomes for most 
questions, and included other outcomes deemed critical for decision making for some questions. 
 
Literature search 
For some questions, with help of professional medical librarians, we electronically searched major databases, 
i.e. Cochrane Central and MEDLINE to identify relevant systematic reviews, randomized controlled trials 
(RCTs), observational studies, and case series. When electronic searches were performed, we searched for 
studies published in English from inception to March 2020. To inform the recommendations on 
hemodynamic and ventilatory support, we used recently published systematic reviews and asked experts to 
identify any new relevant studies. 
 
Selection of studies and data abstraction 
For selected PICO questions, a pair of two reviewers screened titles and abstracts retrieved from the 
bibliographic databases; all potentially eligible studies were assessed for eligibility according to pre-specified 
criteria for each PICO question. Content Experts were queried for any additional studies not identified by the 
search. Subsequently, pairs of reviewers independently abstracted relevant data on the corresponding PICOs, 
and items relevant to risk of bias. 
We obtained intention to treat data whenever available; otherwise we used complete case data, i.e. ignoring 
missing data [6]. 
 
Quality of evidence 
We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach 
to assess the quality of evidence [7], i.e. our confidence in the estimate of the effect to support a 
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recommendation [8]. The quality of evidence was rated as high, moderate, low, or very low [9]. We used the 
GRADEpro guideline development tool (GDT) online software (http://gdt.guidelinedevelopment.org) to 
generate the evidence profiles (evidence summaries) [10]. 
  
Using indirect evidence  
Given the recent emergence of COVID-19, we anticipated limited direct evidence would exist, and therefore 
used a predefined algorithm to decide if indirect evidence could inform a specific question (Figure S1-2). 
The SSC COVID-19 panel decided which population to extrapolate evidence from based on the context of 
the recommendation, and the likelihood of the presence of an effect modifier (Figure S3). Accordingly, we 
used indirect evidence on Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute 
Respiratory Syndrome (SARS), and other coronaviruses, and we considered indirect evidence related to 
supportive care in ICU from studies on influenza and other respiratory viral infections, acute respiratory 
distress syndrome (ARDS) and sepsis.  
 
Recommendation Formulation 
We used the principles outlined in the evidence to decision framework (EtD) to formulate recommendations, 
but because of the tight timelines we did not complete the online EtD tables [11]. The EtD framework covers 
the following domains: priority setting, magnitude of benefit and harm, certainty of the evidence, patient 
values, balance between desirable and undesirable effects, resources and cost, equity, acceptability and 
feasibility.   
Each of the four subgroups drafted the preliminary recommendations. We use the wording “we recommend” 
for strong recommendations and “we suggest” for suggestions (i.e. weak recommendations), the implications 
of the recommendation strength are presented in Table 1. The final list of recommendations was developed 
by panel discussion and consensus, we did not require voting on recommendations. We present the 
guideline’s statements and recommendations in Table 2. 
 
Updating the recommendations 
We will have periodic automated electronic searches sent to assigned panel members every week to identify 
relevant new evidence as it emerges and update the recommendations if needed, or formulate new 
recommendations, in what is known as a “living guideline” model. 
  
I. Infection Control 
 
Risk of SARS CoV-2 transmission 
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A recent report from the Chinese Center of Disease Control and Prevention described 72,314 cases of 
COVID-19 from China, of which 44, 672 were laboratory confirmed. Among laboratory-confirmed cases, 
1716 (3.8%) were healthcare workers, most of which, 63% (1080 of 1716), acquired the infection in Wuhan. 
The report describes that 14.8% (247 of 1668) of infected healthcare workers had severe or critical illness, 
and that 5 died [12]. In Italy, as of March 15, 2020, there are 2026 documented COVID-19 cases among 
healthcare workers [13]. Although incidence data is not available, these data point to a considerable burden of 
infection among healthcare workers.  The risk of patient to patient transmission in ICU is currently unknown, 
therefore, adherence to infection control precautions is paramount.   
 
Healthcare workers should follow the infection control policies and procedures at their healthcare 
institutions. We provide the following recommendations and suggestions as considerations rather than a 
requirement to changing institutional infection control policies. 
 
Recommendation: 
1. For healthcare workers performing aerosol-generating procedures* on patients with COVID-19 in the 
ICU, we recommend using fitted respirator masks (N95 respirators, FFP2, or equivalent), as 
compared to surgical/medical masks, in addition to other personal protective equipment (i.e., gloves, 
gown, and eye protection such as a face shield or safety googles) (best practice statement). 
 
* Aerosol-generating procedures in the ICU include: endotracheal intubation, bronchoscopy, open suctioning, 
nebulized treatment, manual ventilation before intubation, physical proning of the patient, disconnecting the 




Respirator masks are designed to block 95 -99% of aerosol particles, N95 (conform to United States Federal 
Drug Agency standards) and FFP2 (conform to European - European Committee for Standards standards). 
Staff should be fit tested for each different type. Surgical (also known as medical masks) are designed to block 
large particles, droplets and sprays, but are less effective in blocking small particle aerosols (< 5 micrometers) 
[14].  
 
This recommendation is based on a consensus of recommendations from CDC, WHO, and other public 
health organizations, along with epidemiologic data demonstrating that aerosol-generating procedures 
increased risk to healthcare workers during the SARS epidemic. Powered air purifying respirators (PAPRs) 





2. We recommend performing aerosol-generating procedures on ICU patients with COVID-19 in a 
negative pressure room (best practice statement). 
 
Rationale: 
Negative pressure rooms are an engineering control intended to prevent the spread of contagious airborne 
pathogens from room to room (e.g. measles, and tuberculosis). The main goal is to avoid the accidental 
release of pathogens into a larger space and open facility, thereby protecting healthcare workers and patients 
in a hospital setting. A negative air pressure is created in the patient’s room to keep the pathogen inside and 
avoid its diffusion. By adopting this precaution, when aerosol generating procedures like tracheal intubation, 
bronchoscopies, or non-invasive positive pressure ventilation (NIPPV) are performed within the room, there 
is a lower risk of cross-contamination among rooms and infection for staff and patients outside the room.  
Negative pressure is created and maintained by a ventilation system that allows extra air to enter the isolated 
room by differential pressure, and be exhausted directly to the outside or be filtered through a high-efficiency 
particulate air (HEPA) filter directly before recirculation. Moreover, the presence of unnecessary staff in the 
room should be avoided. 
 
Negative pressure rooms have proven to be an effective measure that helped to avoid cross-contamination 
during the SARS epidemic [15]. Accordingly, for aerosol generating procedures; the WHO guidance on 
COVID-19 recommends negative pressure rooms with a minimum of 12 air changes per hour or at least 160 
L/second/patient in facilities with natural ventilation [16]. Bronchoscopies are among the procedures at 
highest risk for aerosolization, and their use should be minimized. Non-invasive ventilation is also at high risk 
of aerosolization, and strategies have been described to contain the risk [17] of virus spread, also according to 
previous report from SARS infection [18].  
 
In case this is not feasible, a portable HEPA filters should be used in the room wherever possible. HEPA 
filter is a mechanical air filter, used for isolation where maximum reduction or removal of submicron 
particulate matter from air is required. HEPA filters have been demonstrated to reduce virus transmission in 
simulated settings [19]. 
 
Recommendations: 
3. For healthcare workers providing usual care for non-ventilated COVID-19 patients, we suggest using 
surgical/medical masks, as compared to respirator masks in addition to other personal protective 




4. For healthcare workers who are performing non-aerosol-generating procedures on mechanically 
ventilated (closed circuit) patients with COVID-19, we suggest using surgical/medical masks as 
compared to respirator masks, in addition to other personal protective equipment. (weak 
recommendation, low quality evidence). 
 
Rationale: 
Our recommendation is in keeping with the WHO guidance, and with the current evidence that suggest 
surgical/medical masks are probably not inferior to N95 respirators for laboratory confirmed seasonal 
respiratory viral infections (e.g., influenza but not measles). We updated the most recent systematic review 
and meta-analysis of RCTs [20], and identified one new RCT [21].  Overall, 4 RCTs (5,549 individuals) 
randomized healthcare workers to N95 respirators or medical masks [21-25].  The use of medical masks, 
compared to N95 respirators, did not increase laboratory confirmed respiratory infection (OR 1.06, 95% CI 
0.90 to 1.25). Although the point estimates suggest that medical masks increased influenza-like illness (OR 
1.31, 95%CI 0.94, 1.85) and clinical respiratory infection (OR 1.49, 95%CI 0.98 to 2.28), the differences were 
not statistically significant. A recent systematic review and meta-analysis reached similar conclusions [26]. 
 
Only one RCT reported on coronavirus, when seasonal coronavirus (OC43, HKU1, 229E, NL63) was tested 
for by PCR in this non-cluster RCT, 4.3% (9/212) nurses in the medical mask group had RT-PCR confirmed 
coronavirus infection compared to 5.7% (12/210) in the N95 respirator group [22].  
 
When making this recommendation, the panel considered the lack of convincing evidence that N95 
respirators improve clinical outcomes, the cost and resources associated with N95 mask use, and the need to 
preserve the N95 respirator supply for aerosol-generating procedures. Therefore, the panel issued a 
suggestion to use medical masks in this context. However, SARS-CoV-2 appears to be more easily 
transmissible and lethal than seasonal influenza.  Specifically, an early estimate of the reproductive number 
(R0) of SAR-CoV-2, the average number an infected person subsequently infects as a function of biological 
properties of the pathogen in combination with social and environmental factors, is 2.3 [27].  By comparison, 
the estimated average R0 of the 1918 influenza pandemic that resulted in an estimated 50 million deaths 
globally was 1.8, and the estimated average R0 for seasonal influenza is 1.28 [28].  Therefore, a minimum of a 
surgical/medical masks is recommended for healthcare workers caring for non-ventilated COVID-19 patients 
and for healthcare workers who are performing non-aerosol-generating procedures on mechanically 
ventilated (closed circuit) patients with COVID-19.  When scarcity is not an issue, use of a fitted respirator 





5. For healthcare workers performing endotracheal intubation on patients with COVID-19, we suggest 




No direct evidence compares the use of video-laryngoscopy over direct laryngoscopy for intubation of 
patients with COVID-19. While SAR-CoV-2 appears to be predominantly spread by large respiratory 
droplets, intubation is likely a small particle (less than 5 micrometers) aerosol-generating procedure, which 
increases the risk of transmission to health care workers [29]. Intubation is particularly risky given the close 
contact of healthcare workers with a patient’s airway and respiratory secretions. Thus techniques which will 
reduce the number of attempts and duration of endotracheal intubation, and minimize the proximity between 
the operator and the patient should be prioritized, potentially reducing the risk of complications to hypoxic 
COVID-19 patients. In a systematic review including 64 studies and 7,044 patients, video-laryngoscopy 
reduced the risk of failed intubation (OR 0.35, 95%CI 0.19 to 0.65), without significant impact upon 
proportion of success of first-pass attempts (OR 0.79, 95%CI 0.48 to 1.3), hypoxia (OR 0.39, 95% CI 0.1 to 
1.44), or time for tracheal intubation [30, 31]. In patients with difficult airways, there may be an improvement 
in first-pass success with video-laryngoscopy [32].  
 
Thus in settings where video-laryngoscopy is available and staff are skilled in its use, we suggest it be used 
over direct laryngoscopy to maximize chances of success. Recognizing that not all centers will have rapid 
access to video-laryngoscopy or skilled users, this recommendation is conditional.  
 
6. For healthcare workers performing endotracheal intubation on patients with COVID-19, we 
recommend endotracheal intubation is performed by healthcare worker experienced with airway 
management, to minimize the number of attempts and risk of transmission (best practice statement). 
 
Rationale: 
Similar to the reasoning above, factors which maximize the chances of first pass success should be used when 
intubating patients with suspected or confirmed COVID-19. Thus, we recommend that the healthcare 
operator with the most experience and skill in airway management should be the first to attempt intubation.  
 
 
II. Laboratory diagnosis and specimens 
 
Indications for testing ICU patients for SARS CoV-2 
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The WHO recently declared a COVID-19 pandemic. Accordingly, every critically ill patient arriving with 
evidence of respiratory infection should be considered at risk for SARS-CoV-2. Real-Time Polymerase Chain 
Reaction (RT-PCR) is the gold standard for similar viral infections, including SARS [33]. Notably, COVID-19 
poses several diagnostic challenges due to the wide incubation period with a mean of 5 days asymptomatic 
shedding for an undetermined interval prior to symptom onset, and potentially discordant shedding from the 
upper versus lower respiratory tract [1, 34]. Accordingly, the performance of biomolecular assay may vary by 
site of sampling. 
 
7. For intubated and mechanically ventilated adults with suspicion of COVID-19:  
 
7.1. We suggest obtaining lower respiratory tract samples for diagnostic testing, over upper 
respiratory tract (nasopharyngeal or oropharyngeal) samples (weak recommendation, low 
quality evidence). 
 
7.2. For lower respiratory samples, we suggest obtaining endotracheal aspirates, over 




COVID-19 diagnosis is based on RT-PCR testing of respiratory samples from nasopharyngeal and 
oropharyngeal swabs and lower respiratory tract samples whenever possible. Bronchoalveolar lavage should 
be limited and performed only if indicated and with adequate precautions, due to risk of aerosolization and 
consequent exposure of healthcare professionals. Similarly, sputum induction should be avoided due to 
increased risk of aerosolization. Tracheal aspirates specimen appears to carry a lower risk of aerosolization, 
and sometimes can be done without disconnecting the patient from the ventilator. 
 
RT-PCR laboratory procedures for SARS CoV-2 have been well described with a number of assays in use 
[35].  Despite generally high sensitivity and specificity of RT-PCR-based assays [36], sole use of oropharyngeal 
swabs specimens for SARS CoV-2 diagnosis may be limited by low negative predictive value. In a recent 
study, only 9 out of 19 (47%) oropharyngeal swabs from COVID-19 patients tested positive by RT-PCR [37].  
Similar data were reported using RT-PCR during the 2002-2003 SARS epidemic [38]. Using seroconversion as 
the “gold standard” for SARS diagnosis, RT-PCR assays performed on nasopharyngeal and throat specimens 
were only positive 65% and 70% of the time, respectively.  However, no false positives were observed 
indicating assay specificity of 100%. Similarly, in a study accounting for CT scan findings among suspected 
COVID-19 cases, 48% with negative oropharyngeal or nasal swabs were considered highly likely cases, and 
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33% were considered probable cases [39].  Consequently, a single negative swab from the upper airway does 
not rule out SARS-CoV-2 infection and repeated sampling from multiple sites inclusive of the lower airway 
will increase diagnostic yield.  Similarly, given that coinfection with other viral pathogens have been observed, 
a positive test for another respiratory virus does not exclude COVID-19, and should not delay testing if 
suspicion for COVID-19 is high [40]. Given high specificity, a single positive swab confirms the diagnosis of 
COVID-19 and is enough to trigger infection control precautions and treated the patient accordingly. 
 
Lower respiratory tract specimens are considered to be higher yield than upper respiratory specimen in 




III. Supportive Care 
 
A) Hemodynamic Support 
 
Shock and cardiac injury in COVID-19 patients 
The reported prevalence of shock in adult patients with COVID-19 is highly variable (from 1% to 35%), 
depending on the patient population studied, severity of illness, and definition of shock. In a recent report 
summarizing the epidemiological characteristics of 44,415 Chinese patients with COVID-19, 2087 (5%) were 
diagnosed as critical cases, defined as severe hypoxemia and/or presence of other organ failure, including 
shock [12]. In another Chinese study of 1099 patients with COVID-19 with similar severity of illness, only 12 
(1.1%) developed shock [1]. In hospitalized patients, the incidence is likely higher [42] (Table 3), and may 
reach up to 20-35% among patients in the ICU [42, 43]. 
 
Cardiac injury (elevation of cardiac injury biomarkers above the 99th percentile upper reference limit) has 
been reported in 7% to 23% of the patients with COVID-19 in Wuhan, China [42-45]. While the prevalence 
of cardiac injury may correlate with the prevalence of shock, our certainty of this association is limited by the 
lack of systematic screening for cardiac dysfunction in hemodynamically stable patients (Table 3). 
 
The prognosis of patients with COVID-19 and shock has not been systematically reported. In a study of 150 
patients from 2 hospitals in Wuhan in China, shock was a major reason for death in 40%, which may be at 
least partly due to fulminant myocarditis [46].  
Studies on risk factors associated with shock in patients with COVID-19 are lacking. Few reports are 
available, however the majority report unadjusted estimates [12, 42, 46]. Despite methodological limitations, 
these studies suggest that older age, comorbidities (especially diabetes, and cardiovascular disease including 
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8. For adults with COVID-19 and shock, we suggest using dynamic parameters, skin temperature, 
capillary refilling time, and/or lactate over static parameters to assess fluid responsiveness (weak 
recommendation, low quality evidence). 
 
Rationale: 
No direct evidence addresses the optimal resuscitation strategy in patients with COVID-19 and shock, 
therefore, the panel used indirect evidence from critically ill patients in general to inform this 
recommendation.  
 
In a systematic review and meta-analysis of 13 RCTs (n=1,652) examining the effect of dynamic assessment 
of fluid therapy on patient important outcomes in adult ICU patients requiring fluid resuscitation[47], 
dynamic assessment to guide fluid therapy reduced mortality (RR 0.59, 95% CI 0.42 to 0.83), ICU length of 
stay (MD –1.16 days, 95% CI –1.97 to –0.36), and duration of mechanical ventilation (-2.98 hours, 95% CI -
5.08 to -0.89). Of note, only 1 trial focused on patients with septic shock. Dynamic parameters used in these 
trials included stroke volume variation (SVV), pulse pressure variation (PPV), and stroke volume change with 
passive leg raise or fluid challenge. Among the examined dynamic parameters, passive leg raising, followed by 
PPV and SVV appear to predict fluid responsiveness with highest accuracy [48]. The static parameters 
included components of early goal directed therapy, e.g. central venous pressure (CVP) and mean arterial 
pressure (MAP).  
 
Resuscitation of patients with shock based on serum lactate levels has been summarized in a systematic 
review and meta-analysis of 7 RCTs (n=1,301) [49]. Compared with central venous oxygen saturation 
(ScVO2) guided therapy, early lactate clearance-directed therapy was associated with a reduction in mortality 
(RR 0.68, 95% CI 0.56 to 0.82), shorter ICU length of stay (MD 1.64 days, 95% CI -3.23 to -0.05), and 
shorter duration of mechanical ventilation (MD -10.22  hours, 95% CI -15.94 to -4.50). However, a high 
lactate level does not always indicate hypovolemia; it may also be caused by mitochondrial dysfunction, liver 




In the ANDROMEDA-SHOCK trial, capillary refill testing (CRT) every 30 min was associated with a non-
significant reduction in mortality (HR 0.75, 95% CI 0.55 to 1.02), compared to serum lactate measurement 
every 2 hours [50]. CRT is a simple and easy test that can be used in almost any setting. Due to possible 
improvements in mortality, length of stay, and duration of mechanical ventilation, and their availability, we 
suggest using dynamic parameters, skin temperature, capillary refilling time, and/or lactate over static 
parameters to assess fluid responsiveness in patients with COVID-19 and shock. 
 
Recommendation: 
9. For the acute resuscitation of adults with COVID-19 and shock, we suggest using a conservative, 
over a liberal fluid strategy (weak recommendation, very low quality evidence).  
 
Rationale: 
No direct evidence exists on patients with COVID-19 and shock, therefore, the panel used indirect evidence 
from critically ill patients with sepsis and ARDS to inform this recommendation. 
A recent systematic review of 9 RCTs (n=637) comparing restrictive versus liberal fluid volumes in the initial 
resuscitation of patients with sepsis, found no statistically significant difference in mortality (RR 0.87, 95% CI 
0.69 to 1.10) and serious adverse events (RR 0.91, 95% CI 0.78 to 1.05) [51]. However, all assessed outcomes 
favored lower (conservative) fluid therapy. Importantly, both the quantity and quality of evidence was judged 
as very low, suggesting that more research is needed.   
Correspondingly, in a meta-analysis of 11 RCTs (n=2,051) from 2017, adults and children with ARDS or 
sepsis managed according to a conservative fluid strategy in the post-resuscitation phase of critical illness had 
more ventilator-free days and shorter  length of ICU stay, compared with patients managed according to a 
liberal fluid strategy [52] (see section on respiratory support for more details). In a large RCT of 3,141 febrile 
African children from 2011 (FEAST), children randomized to fluid boluses with saline or albumin had 
increased mortality, as compared to children not receiving fluid boluses [53].  
 
In the absence of data demonstrating a benefit from the use of liberal fluid strategies in critically ill patients 
with sepsis or ARDS, and with the majority of COVID-19 patients in the ICU developing ARDS, we suggest 
an initial conservative approach to fluid resuscitation in patients with COVID-19 and shock.  
 
Recommendation: 
10. For the acute resuscitation of adults with COVID-19 and shock, we recommend using crystalloids 





There is no direct evidence on patients with COVID-19 and shock, therefore, the panel used indirect 
evidence from critically ill patients in general to inform this recommendation. 
A systematic review of 69 RCTs (n=30,020) compared the use of crystalloids to colloids in critically ill 
patients [54], identified no outcomes favored the use of colloids. With some colloids being harmful (see 
below), all colloids being more costly than crystalloids, and with limited availability of colloids in some 
settings (e.g. some low- and middle-income countries), we recommend using crystalloids for fluid 
resuscitation in patients with COVID-19 and shock.   
 
Recommendation: 
11. For the acute resuscitation of adults with COVID-19 and shock, we suggest using buffered/balanced 
crystalloids over unbalanced crystalloids (weak recommendation, moderate quality evidence). 
 
Rationale: 
No direct evidence addresses this question in patients with COVID-19 and shock; the panel used indirect 
evidence from critically ill patients in general to inform this recommendation. 
A systematic review and meta-analysis of 21 RCTs (n=20,213) comparing intravenous buffered (balanced) 
crystalloid solutions versus 0.9% saline for resuscitation of critically ill adults and children [55] reported no 
significant difference in hospital mortality (OR 0.91, 95% CI 0.83 to 1.01) or acute kidney injury (OR 0.92, 
95% CI 0.84 to 1.00) with the use of buffered crystalloids. However, the point estimates for both outcomes  
suggest the potential for benefit from buffered crystalloid solutions. In the absence of apparent harm, and 
roughly equivalent costs, we suggest using buffered crystalloid solutions over unbalanced crystalloid solutions 
for resuscitation of patients with COVID-19 and shock. In settings with limited availability of buffered 
solutions, 0.9% saline remains a reasonable alternative.  
 
Recommendation: 
12. For the acute resuscitation of adults with COVID-19 and shock, we recommend against using 
hydroxyethyl starches (strong recommendation, moderate quality evidence). 
 
Rationale: 
There is no direct evidence on patients with COVID-19 and shock. Therefore, the panel used indirect 
evidence from critically ill patients in general to inform this recommendation. 
In a systematic review of 69 RCTs (n=30,020) on crystalloids versus colloids in critically ill patients, use of 
crystalloids was compared to starches in 24 RCTs (n=11,177) [54]. When pooled, no statistically significant 
difference in mortality was observed at end of follow-up (RR 0.97, 95% CI 0.86 to 1.09), within 90 days (RR 
1.01, 95% CI 0.90 to 1.14), or within 30 days (RR 0.99, 95% CI 0.90 to 1.09). The authors, however, report an 
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increased risk of blood transfusion (RR 1.19, 95% CI 1.02 to 1.39) and renal replacement therapy (RRT) (RR 
1.30, 95% CI 1.14 to 1.48).  With clinically important harm and no suggestion of benefits from the use of 
hydroxyethyl starches, we recommend against using hydroxyethyl starches for resuscitation of patients with 
COVID-19 and shock. 
 
Recommendation: 
13. For the acute resuscitation of adults with COVID-19 and shock, we suggest against using gelatins 
(weak recommendation, low quality evidence). 
 
Rationale: 
No study evaluated this question in patients with COVID-19 and shock; the panel used indirect evidence 
from critically ill patients in general to inform this recommendation. In a systematic review of 69 RCTs 
(n=30,020) on crystalloids versus colloids in critically ill patients, crystalloids were compared to gelatins in 6 
RCTs (n=1,698) [54]. No statistically significant difference in all-cause mortality was observed at end of 
follow-up (RR 0.89, 95% CI 0.74 to 1.08), within 90 days (RR 0.89, 95% CI 0.73 to 1.09), or within 30 days 
(RR 0.92, 95% CI 0.74 to 1.16), though point estimates favored the use of crystalloids. In the absence of any 
benefit, and with higher costs, we suggest against using gelatins for resuscitation of patients with COVID-19 
and shock.  
 
Recommendation: 
14. For the acute resuscitation of adults with COVID-19 and shock, we suggest against using dextrans 
(weak recommendation, low quality evidence) 
 
Rationale: 
There is no direct evidence on patients with COVID-19 and shock, therefore, the panel used indirect 
evidence from critically ill patients in general to inform this recommendation. 
A systematic review and meta-analysis on crystalloids versus colloids in critically ill patients, identified 19 trials 
comparing crystalloids to dextrans (n=4,736) [54]. It reported similar mortality at end of follow-up (RR 0.99, 
95% CI 0.88 to 1.11) and within 90 days (RR 0.99, 95% CI 0.87 to 1.12), but a possibly increased risk of 
blood transfusion in the dextran arm (RR 0.92, 95% CI 0.77 to 1.10). 
With a possible increased risk of blood transfusion (bleeding) and higher costs, we suggest against using 





15. For the acute resuscitation of adults with COVID-19 and shock, we suggest against the routine use 
of albumin for initial resuscitation (weak recommendation, moderate quality evidence). 
 
Rationale: 
There is no direct evidence on patients with COVID-19 and shock, therefore, the panel used indirect 
evidence from critically ill patients in general to inform this recommendation. 
A systematic review and meta-analysis identified 20 RCTs (n=13,047) comparing albumin to crystalloids [54]. 
It demonstrated no significant difference in all-cause mortality at end of follow-up (RR 0.98, 95% CI 0.92 to 
1.06), within 90 days (RR 0.98, 95% CI 0.92 to 1.04), or within 30-days (RR 0.99, 95% CI 0.93 to 1.06). The 
risk of blood transfusion (RR 1.31, 95% CI 0.95 to 1.80) and RRT (RR 1.11, 95% CI 0.96 to 1.27) were also 
similar. 
 
In the absence of benefit, and the cost and limited availability of albumin, we suggest against its routine use 





16. For adults with COVID-19 and shock, we suggest using norepinephrine as the first-line vasoactive 
agent, over other agents (weak recommendation, low quality evidence). 
 
Rationale: 
There is no direct evidence on patients with COVID-19 and shock, therefore, the panel used indirect 
evidence from critically ill patients in general to inform this recommendation. A systematic review of 28 
RCTs (n=3,497) and a clinical practice guideline from 2016 summarized the available body of evidence on the 
best first-line vasopressor for patients with shock [56, 57].  
As norepinephrine is the most widely studied vasoactive agent with low a priori risk of undesirable effects, we 
suggest using norepinephrine as the first-line vasoactive agent in patients with COVID-19 and shock.    
 
Recommendation: 
17. If norepinephrine is not available; for adults with COVID-19 and shock, we suggest using either 
vasopressin or epinephrine as the first-line vasoactive agent, over other vasoactive agents (weak 





In the absence of direct evidence on patients with COVID-19 and shock, the panel used indirect evidence 
from critically ill patients in general to inform this recommendation. In a systematic review of 28 RCTs 
(n=3,497) norepinephrine was compared to both vasopressin and epinephrine, but no trials directly compared 
the 2 options [57]. If norepinephrine is not available, we suggest using either vasopressin or epinephrine, as 
both agents have been assessed in RCTs without clear evidence for harm. The choice between vasopressin 
and epinephrine may include availability and contraindications to the two agents. For vasopressin, digital 
ischemia may be a concern; for epinephrine tachycardia and excess lactate production may be considerations. 
 
Recommendation: 
18. For adults with COVID-19 and shock, we recommend against using dopamine if norepinephrine is 
available (strong recommendation, high quality evidence). 
 
Rationale: 
Because no direct evidence addresses that question in patients with COVID-19 and shock, the panel used 
indirect evidence from critically ill patients in general to inform this recommendation. 
A 2016 Cochrane systematic review found 6 RCTs (n=1,400) comparing norepinephrine and dopamine in 
patients with shock [57]. When pooled, the results show no significant difference in all-cause mortality, but 
the point estimate favored norepinephrine (RR 1.07, 95% CI 0.99 to 1.16), and an increased risk of 
arrhythmias (RR 2.34, 95% CI 1.46 to 3.78) in the dopamine arm.  
 
Based on an increased risk of harm including possible increased risk of mortality in patients treated with 
dopamine, we recommend against using dopamine in patients with COVID-19 and shock where 
norepinephrine or alternatives are available (see recommendation 17). 
 
Recommendation: 
19. For adults with COVID-19 and shock, we suggest adding vasopressin as a second-line agent, over 
titrating norepinephrine dose, if target mean arterial pressure (MAP) cannot be achieved by 
norepinephrine (weak recommendation, moderate quality evidence). 
 
Rationale: 
In the absence of data on patients with COVID-19 and shock, the panel used indirect evidence from critically 
ill patients in general to inform this recommendation. 
In a recent clinical practice guideline, the use of vasopressin and vasopressin analogues in critically ill adults 
with distributive shock was assessed [58]. Based on 25 RCTS (n= 3,737), the authors found low certainty of a 
reduction in mortality (RR 0.91, 95% CI 0.85 to 0.99), high certainty of a reduction in atrial fibrillation (RR 
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0.77, 95% CI 0.67 to 0.88), and moderate certainty of an increased risk of digital ischemia (RR 2.56, 95% CI 
1.24 to 5.25) with the addition of vasopressin or its analogues to catecholamines. Another recent systematic 
review reached similar conclusion [59]. Based on these findings, we suggest adding vasopressin as a second-
line agent, over titrating norepinephrine dose, if target MAP cannot be achieved by norepinephrine in patients 
with COVID-19 and shock. 
 
Recommendation: 
20. For adults with COVID-19 and shock, we suggest titrating vasoactive agents to target a MAP of 60-65 
mmHg, over higher MAP targets (weak recommendation, low quality evidence) 
 
Rationale: 
No direct evidence informs this recommendation and the panel used indirect evidence from critically ill 
patients generate this recommendation. A recent individual patient-data meta-analysis of 2 RCTs (n=894) 
comparing higher versus lower blood pressure targets for vasopressor therapy in adult patients with shock 
reported no significant difference in 28-day mortality (OR 1.15, 95% CI 0.87 to 1.52), 90-day mortality (OR 
1.08, 95% CI 0.84 to 1.44), myocardial injury (OR 1.47, 95% CI 0.64 to 3.56) or limb ischemia (OR 0.92, 95% 
CI 0.36 to 2.10) [60]. The risk of arrhythmias was increased in patients allocated to the higher target group 
(OR 2.50, 95% CI 1.35 to 4.77). Correspondingly, the recently published 65 trial reports an absolute risk 
difference in mortality of 3% (RR 0.93, 95% CI 0.85-1.03) in favor of a MAP target of 60-65 mmHg (lower 
target), as compared to a standard of care MAP target (higher target) [61].  
 
With an indication of improved outcome with lower MAP targets (and no firm indication of harm), we 
suggest titrating vasoactive agents to a target of 60-65 mmHg.  
  
Recommendation: 
21. For adults with COVID-19 and shock with evidence of cardiac dysfunction and persistent 
hypoperfusion despite fluid resuscitation and norepinephrine, we suggest adding dobutamine, over 
increasing norepinephrine dose (weak recommendation, very low quality evidence). 
 
Rationale: 
In the absence of direct evidence in patients with COVID-19 and shock, the panel used indirect evidence 
from critically ill patients to inform this recommendation. In a clinical practice guideline from 2018 assessing 
the optimal inotropic agent in patients with acute circulatory failure (shock), no RCTs comparing dobutamine 
vs. placebo or no treatment were identified [62]. Based on a physiological rationale, we suggest adding 
dobutamine over no treatment in patients with COVID-19 and shock with evidence of cardiac dysfunction 
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and persistent hypoperfusion despite fluid resuscitation and high doses of norepinephrine. Use of 
dobutamine in shock, including in COVID-19 patients with shock, is a research priority.  
 
Recommendation:  
22. For adults with COVID-19 and refractory shock, we suggest using low-dose corticosteroid therapy 
(“shock-reversal”), over no corticosteroid therapy (weak recommendation, low quality evidence). 
Remark: A typical corticosteroid regimen in septic shock is intravenous hydrocortisone 200 mg per day either 
as an infusion or intermittent doses. 
Rationale: 
No data exist on steroids in patients with COVID-19 and shock, therefore, the panel used indirect evidence 
from critically ill patients in general to inform this recommendation. A 2018 systematic review of 22 RCTs 
(n=7297) on low-dose corticosteroid therapy versus no corticosteroid therapy in adult patients with septic 
shock [63] and a clinical practice guideline [64] report no significant difference in short-term mortality (RR 
0.96, 95% CI 0.91 to 1.02), long-term mortality (RR 0.96, 95% CI 0.90 to 1.02) or serious adverse events (RR 
0.98, 95% CI 0.90 to 1.08). However, time to resolution of shock, and length of stay in ICU and in hospital 
were shorter with corticosteroid therapy.  
 
As time to resolution of shock and length of stay (especially in ICU) are important considerations with 
regards to costs, we suggest using low-dose corticosteroid therapy in patients with COVID-19 and refractory 
shock. We provide further guidance for patients with COVID-19 and respiratory failure in the absence of 
refractory shock below. 
 
B) Ventilatory Support 
 
The prevalence of hypoxic respiratory failure in patients with COVID-19 is 19% [12], recent reports from 
China showed that 4 to 13% of COVID-19 patients in these studies received non-invasive positive pressure 
ventilation (NIPPV), and that 2.3 to 12% required invasive mechanical ventilation (Table 3) [1, 12, 42, 43, 
65]. The true incidence of hypoxic respiratory failure in patients with COVID-19 is not clear, however, it 
appears that about 14% of the patients will develop severe disease requiring oxygen therapy, and 5% will 
require ICU admission and mechanical ventilation [12].  Another study reported on 52 critically ill COVID-19 
patients, 67% of patients had ARDS, 33 (63.5%) of patients received high-flow nasal cannula (HFNC), 56% 
invasive mechanical ventilation and 42% received NIPPV [42].  
 




Risk factors associated with respiratory failure requiring mechanical ventilation are not clearly described in 
published reports, although from the limited available data, risk factors associated with a critical illness/ICU 
admission included older age (>60 years), male gender, presence of underlying comorbidities such as diabetes, 
malignancy, and immunocompromised state [1, 12, 42, 43]. The CDC reported an overall case-fatality rate 
(CFR) of 2.3%, with a CFR of 14.8% in patients 80 years or older. In critically ill patients, the CFR was 49.0% 
and higher than 50% in those who received invasive mechanical ventilation. The presence of  pre-existing 
comorbid condition such as cardiovascular disease, diabetes, chronic respiratory disease, hypertension, and 
cancer were associated with higher risk of death [12]. 
  
Recommendation:  
23. For adults with COVID-19, we suggest starting supplemental oxygen if the peripheral oxygen saturation 
(SPO2) is < 92%, and recommend starting supplemental oxygen if SPO2 is < 90%  
 
24. For adults with COVID-19 and acute hypoxemic respiratory failure on oxygen; we recommend that 
SPO2 be maintained no higher than 96% (strong recommendation, moderate quality evidence). 
 
Rationale: 
A recent study described the disease course of 1,009 patients with COVID-19 in China and showed that 41% 
of all hospitalized patients and over 70% of those with severe disease required supplemental oxygen [1]. In 
critically ill patients, hypoxia can be detrimental and is associated with poor outcomes [66]. There are no 
randomized or non-randomized studies on the use of oxygen in adults with COVID-19. However, the panel 
used indirect evidence from the acutely ill population to inform the recommendations. 
 
A systematic review and meta-analysis of 25 RCTs (16,037 patients) showed that a liberal oxygen strategy is 
associated with increased risk of hospital mortality (RR1.21, 95%CI 1.03 to 1.43) in acutely ill patients [67]. 
Furthermore, meta-regression showed a linear association between risk of death and higher SPO2 targets [67]. 
The median SPO2 in the liberal oxygen group was 96% (IQR 96 to 98) across all trials. A recent clinical 
practice guideline recommended that SPO2 be maintained no higher than 96%[68].  
 
Subsequent trials provided further guidance on oxygenation targets. The ICU-ROX trial randomized 1000 
critically ill patients to receive either conservative oxygen (based on a protocol to dial down oxygen) or usual 
care, this trial showed no difference in 180-day mortality between the two groups (OR 1.05, 95% CI 0.81 to 
1.37) [69]. The ICU-ROX trial did not compare hyperoxia to a conservative oxygen strategy, instead it 
compared usual care to a conservative oxygen strategy.  
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The recent LOCO2 trial randomized patients with ARDS to a conservative oxygen arm (target SPO2 88 to 
92%) or a liberal oxygen arm (target PO2 ≥96%). The trial was stopped early for futility and possible harm 
after including 205 patients with 61 death events for the primary outcome of 28-day mortality (risk difference 
[RD] 7.8%, 95% CI; −4.8 to 20.6) [70]. At 90 days, the conservative oxygen arm had higher risk of death (RD 
14.0%, 95% CI, 0.7 to 27.2).  
 
Given the associated patient-harm at the extremes of SPO2 targets and increased cost with liberal oxygen use, 
and the potential to reduce equity if oxygen resources are depleted; the panel issued a strong recommendation 
against using oxygen to target SPO2>96%, and a strong recommendation to avoid lower SPO2<90%. 
Therefore, a reasonable SPO2 range for patients receiving oxygen is 92% to 96%. 
 
Recommendation:  
25. For adults with COVID-19 and acute hypoxemic respiratory failure despite conventional oxygen 




There is no direct evidence on patients with COVID-19, therefore, the panel used indirect evidence from the 
critically ill population to inform this recommendation. In an RCT comparing HFNC to conventional oxygen 
therapy for patients with acute hypoxic respiratory failure, HFNC resulted in reduced 90-day mortality (OR 
0.42, 95% CI 0.21 to 0.85) but did not reduce the risk of intubation [71]. A systematic review and meta-
analysis of 9 RCTs (2,093 patients) showed that HFNC reduces intubation compared to conventional oxygen 
(RR 0.85, 95% CI 0.74 to 0.99) but does not affect risk of death or ICU length of stay.[72-74] Even though 
evidence for mortality and length of stay is not as strong, the reduction in need for intubation is especially 
important in pandemics such as COVID-19 where resources such as critical care beds and ventilators may 
become limited. In addition, in SARS, there are reports of increased transmission of disease to health care 
workers with endotracheal intubation, especially for nurses (OR 6.6, 95% Cl 2.3 to 18.9) [29, 75, 76]. While 
this is based mostly on retrospective observational studies, HFNC does not seem to confer an increased risk 
of transmission of disease. In studies evaluating bacterial environmental contamination, HFNC resulted in 
similar contamination risk as conventional oxygen [77]. In SARS, healthcare workers exposed to HFNC were 
not at increased risk of developing disease [75]. Finally, patients may find HFNC more comfortable or at least 
as comfortable as conventional oxygen therapy [71, 74]. Although some authors advised avoiding the use of 
HFNC in patients with COVID-19 due to fear of disease transmission, studies supporting this advice are 
lacking [78]. Although some have proposed that patients wear face masks while on HFNC therapy; we are 






26. For adults with COVID-19 and acute hypoxemic respiratory failure, we suggest using HFNC over 
NIPPV (weak recommendation, low quality evidence). 
  
Rationale: 
In adults with COVID-19 and acute respiratory failure, we suggest the use of HFNC over NIPPV. In an RCT 
comparing HFNC to NIPPV for patients with acute hypoxic respiratory failure, HFNC resulted in reduced 
mortality at 90 days (HR 2.50, 95% CI 1.31 to 4.78) but did not significantly affect the need for intubation 
(50% failure rate in NIPPV vs 47% in conventional oxygen and 40% in HFNC; p=0.18) [71]. Another meta-
analysis comparing HFNC to NIPPV have shown HFNC to decrease the need for intubation of patients 
compared to NIPPV without significantly reducing mortality or ICU length of stay [72]. Additionally, patients 
may find HFNC more comfortable than NIPPV [71]. Given the evidence for decreased risk of intubation 
with HFNC compared to NIPPV in acute hypoxemic respiratory failure and studies suggesting that NIPPV 
may confer greater risk for nosocomial infection of healthcare providers for infected patients, we suggest 
HFNC over NIPPV. However, any patients receiving HFNC or NIPPV should be monitored closely and 
cared for in a setting where intubation can be facilitated in the event of decompensation, as the failure rate 
may be high and emergent intubation in an uncontrolled setting may increase the risk of nosocomial infection 
in healthcare providers [79, 80].  
 
Recommendations: 
27. For adults with COVID-19 and acute hypoxemic respiratory failure, if HFNC is not available and no 
emergent indication for endotracheal intubation; we suggest a trial of NIPPV with close monitoring and 
short interval assessment for worsening of respiratory failure (weak recommendation, very low-quality 
evidence).  
 
28. We were not able to make a recommendation regarding the use of helmet NIPPV compared to mask 
NIPPV, it is an option, but we are not certain about its safety or efficacy in COVID-19  
 
29. For adults with COVID-19 receiving NIPPV or HFNC, we recommend close monitoring for worsening 






In adults presenting with hypoxic respiratory failure from COVID-19, there is no direct evidence to support 
the use of NIPPV, furthermore, some prior studies suggested an increase in the risk of infection transmission 
to healthcare workers. Meta-analyses of RCTs showed reduction in both intubation and mortality risks with 
NIPPV in hypoxic respiratory failure. However, these meta-analyses included studies focused on the 
immunocompromised, acute cardiogenic pulmonary edema, or post-operative patients, which may not be as 
applicable to COVID-19 patients, where acute hypoxemic respiratory failure and ARDS are more common 
presentations.[43, 81-83] In acute hypoxemic respiratory failure from an etiology other than cardiogenic 
pulmonary edema, NIPPV has a high rate of failure.  In one RCT, 49% of patients with hypoxic respiratory 
failure ventilated with NIPPV failed and required intubation [71].  In addition, patients with hypoxic 
respiratory failure randomized to NIPPV had higher mortality (28%, 95% CI 21%-37%) compared to 
conventional oxygen therapy (23%, 95% CI 16%-33%) and HFNC (13%, 95% CI 7%-20%) (p=0.02). 
 
In a cohort of Middle East Respiratory Syndrome (MERS) patients, NIPPV was not associated with 
improved mortality or length of stay, compared to patients who were intubated without NIPPV trial [79]. 
However, NIPPV was associated with a high failure rate (92.4%), leading to intubation.  Patients that had 
NIPPV prior to intubation had increased requirements for inhaled nitric oxide and increased mortality [79]. 
Failure rates in other pandemics such as influenza, H1N1 and SARS ranges from 10-70% with demonstration 
of efficacy supported mostly by case series and observational studies rather than RCTs, leading to practice 
variation. In China, use of NIPPV for pandemic respiratory infection is common while guidelines from 
Europe, Hong Kong, and US advise against NIPPV as first line therapy in H1N1 [84]. There are additional 
concerns for the use of NIPPV in respiratory pandemics like COVID-19. NIPPV may aggravate severe 
forms of lung injury with injurious transpulmonary pressures and large tidal volumes [85, 86], and may delay 
initiation of invasive mechanical ventilation, leading to emergent or more unstable intubations that can 
increase the risk of transmission to the care team [85]. In addition, NIPPV is an aerosol generating procedure 
that can increases risk of transmission of disease to healthcare workers [29]. Several other studies and meta-
analyses of SARS have also highlighted the risk of nosocomial spread of SARS with NIPPV [76, 87].  
 
The balance between benefit and harm with using NIPPV in adults with COVID-19 is unclear.  In other 
forms of respiratory failure such as acute hypercapnic respiratory failure or acute cardiogenic pulmonary 
edema, NIPPV may be beneficial if this is the cause of respiratory failure for certain COVID-19 patients [88, 
89].   However, because limited experience with NIPPV in pandemics suggests a high failure rate, we 
recommend that any patients receiving NIPPV be monitored closely and cared for in a setting where 
intubation can be facilitated in the event of decompensation [79, 80]. When resources become stretched, 
there may be insufficient ability to provide invasive ventilation, even a moderate chance of NIPPV success, 




If NIPPV is used, a helmet NIPPV is an attractive option, if available. A single-center RCT showed decreased 
intubation and improved mortality from NIPPV by helmet in ARDS patients [90]. Of particular importance 
in the setting of pandemic such as COVID-19, NIPPV by helmet has also been shown to reduce exhaled air 
dispersion, whereas face masks were insufficient [91]. However, helmet NIPPV are more expensive, and 
without direct evidence of benefit in COVID-19 patients, resources should not be utilized to acquire this 
equipment if not already available. Figure 2 summarizes the recommendations on HFNC and NIPPV in 
patients with COVID-19. 
 
Invasive Mechanical Ventilation 
 
Recommendation: 
30. For mechanically ventilated adults with COVID-19 and ARDS, we recommend using low tidal volume 
(Vt) ventilation (Vt 4-8 mL/kg of predicted body weight), over higher tidal volumes (Vt>8 mL/kg) 
(strong recommendation, moderate quality evidence). 
 
Rationale: 
Currently there are no studies addressing the mechanical ventilation strategies of COVID-19 patients. 
However, the panel of experts believe that mechanically ventilated patients with COVID-19 should be 
managed similar to other patients with acute respiratory failure in the ICU. 
While mechanical ventilation is potentially  life-saving intervention, it can worsen lung injury and contribute 
to multiorgan failure in patients with ARDS via ventilator induced lung injury (VILI) [86]. One of the main 
ventilator strategies to minimize VILI is low Vt ventilation. 
 
A systematic review and meta-analysis of RCTs found an inverse association between larger Vt gradient and 
mortality [92]. In addition, authors found that using a protocolized low Vt strategy with high PEEP (9 RCTs 
and 1,629 patients) to reduce the risk of death (RR, 0.80, 95% CI, 0.66 to 0.98)[92]. Our analysis of 5 RCTs 
(1181 patients) showed reduction in hospital mortality with low Vt ventilation (RR 0.73, 95% CI 0.63 to 
0.85)[93-98]. Based on the available body of evidence, several guidelines recommended using low Vt (4-8 
mL/kg of predicted body weight) in patients with ARDS [99, 100]. 
 
The panel judged the magnitude of benefit to be moderate, the cost to be low, and the intervention to be 
acceptable and feasible to implement, and they therefore, issued a strong recommendation for using low Vt 




The ARDSNet study protocol set the initial Vt at 6 ml/kg which can be increased to 8 ml/kg if the patient is 
double triggering or if inspiratory airway pressure decreases below PEEP [95]. 
Strict adherence to target Vt in spontaneously breathing patients with ARDS is a challenge, patient-ventilator 
dyssynchrony is not uncommon [101]. 
 
Recommendation: 
31. For mechanically ventilated adults with COVID-19 and ARDS, we recommend targeting plateau 
pressures (Pplat) of < 30 cm H2O (strong recommendation, moderate quality evidence). 
 
Rationale: 
There are no clinical trials examining the effect of plateau pressure (Pplat) limitation on COVID-19 induced 
ARDS. However, there is a large body of indirect evidence in patients with ARDS. Along with low Vt 
ventilation, Pplat limitation is a lung protective strategy to limit VILI. A systematic review and meta-analysis 
of RCTs found that using a lung protective strategy including protocolized low Vt and Pplat < 30 cmH2O (9 
RCTs and 1,629 patients) to reduce the risk of death (RR, 0.80, 95% CI, 0.66 to 0.98)[92]. A subsequent 
meta-analysis of RCTs comparing ventilatory strategies with low and high Pplat in patients with ARDS (15 
studies) found that short-term mortality was higher in patients with Pplat > 32 cmH2O during the first week 
in the ICU (Day 1: RR 0.77, 95% CI 0.66 to 0.89; Day 3: RR 0.76, 95% CI 0.64-0.90; Day 7: RR 0.78, 95% CI 
0.65-0.93)[102]. 
Based on the available body of evidence, several guidelines recommended keeping Pplat < 30 cm H2O in 
patients with ARDS [99, 100]. 
The panel judged the magnitude of benefit to be moderate, the cost to be low, the patients’ values to be 
consistent, and the intervention to be acceptable and feasible to implement, therefore, issued a strong 
recommendation keeping Pplat < 30 cmH2O when ventilating patients with ARDS. 
 
Practical considerations: 
The ARDSNet study protocol set the initial Vt at 6 ml/kg, and then measured Pplat (after a 0.5 second 
inspiratory pause) [95]. If the Pplat > 30 cmH2O, Vt could be reduced in 1 mL/kg  (to 4 mL/kg) increments 
until Pplat was within range.  
 
Recommendation: 
32. For mechanically ventilated adults with COVID-19 and moderate to severe ARDS, we suggest using a 








In ARDS, extrinsic PEEP is used to prevent repeated opening and closing of alveoli (i.e. atelectotrauma), 
therefore, reducing VILI. In addition, PEEP increases and sustains alveolar recruitment, which improves 
oxygenation and reduces oxygen requirement. 
 
There are no clinical trials examining the effect of PEEP on coronavirus induced ARDS. However, there is a 
large body of indirect evidence in patients with ARDS. An individual patient data meta-analysis (IPDMA) of 
the 3 largest trials (2,299 patients) of high PEEP [103-105] found no difference in in-hospital mortality in all 
patients (RR 0.94, 95% CI 0.86 to 1.04) [106]. However, in patients with ARDS, a higher PEEP strategy 
resulted in lower ICU mortality (RR 0.85, 95% CI 0.76 to 0.95), in-hospital mortality (RR 0.90, 95% CI 0.81 
to 1.0), and reduction in the use of rescue therapies (RR 0.63, 95% CI 0.53 to 0.75), at the expense of possible 
increase in the risk of pneumothorax [106].  
 
A recent systematic review and meta-analysis of 9 RCTs (3,612 patients) examined the effect of high PEEP 
strategy on patient-important outcomes [107]. Overall, higher PEEP strategy did not reduce hospital 
mortality (RR 0.92, 95% CI, 0.79 to 1.07); However, in subgroup of trials that enrolled patients with 
oxygenation response to PEEP (6 RCTS, 1,888 patients), the use of high PEEP significantly reduced in-
hospital mortality, compared to lower PEEP strategy (RR 0.83, 95% CI 0.69 to 0.98). Although the body of 
evidence suggests a beneficial effect of higher PEEP in selected patients, the results are likely to be 
confounded by not using low Vt ventilation in the control arm of these trials [108]. 
 
There is no the clear and agreed upon definition of higher PEEP, moreover, the optimal PEEP level in 
ARDS patients is unknown, and is likely to vary based on the extent of disease, lung compliance, and other 
factors. In the aforementioned IPDMA, the median PEEP level in the high PEEP arm was 15.3 and 13.3 cm 
H2O on days 1 and 3, respectively, compared to a median of 9 and 8.2 cm H2O on days 1 and 3 in the low 
PEEP arm [106]. Although arbitrary, clinicians could consider a PEEP levels > 10 cm H2O as higher PEEP 
strategy, and PEEP <10 cm H2O as a lower PEEP strategy. 
 
Practical considerations: 
Because the IPDMA combined different strategies to set higher PEEP, a reasonable starting point would be 
to implement a strategy used in the large RCTs that were included (i.e., ALVEOLI, LOV, and ExPRESS) 
[103-105]. After increasing the PEEP level, clinicians should monitor their patients for evidence of 
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barotrauma. Importantly, higher PEEP may result in higher Pplat, which is associated with its own risks and 
benefits when Pplat > 30 cmH2O. Clinicians can use the ARDS Network protocol strategies to determine the 
optimal PEEP level, other strategies are available such as decremental PEEP strategy, esophageal balloon, 




33. For mechanically ventilated adults with COVID-19 and ARDS, we suggest using a conservative fluid 
strategy over a liberal fluid strategy (weak recommendation, low quality evidence). 
  
Rationale: 
The optimal fluid strategy in COVID-19 is not known, however, it is plausible to assume that these patients 
will respond to fluid similar to other ARDS patients. Based on the limited data on COVID-19, cardiac failure 
has been reported to be the cause of death in 40% of COVID-19 deaths, alone or with respiratory failure 
[46]. Another study showed that 44% of COVID-19 patients had arrhythmia[43]. The data suggest 
myocardial injury in some patients with COVID-19.  In ARDS, few RCTs have been published that compare 
conservative or de-resuscitative and liberal fluid strategies. A recent systematic review included 5 RCTs 
enrolling 1,206 patients with ARDS. The risk of death was similar in both groups, 28 % in the conservative 
fluid strategy group and 31.1% in the liberal strategy group (RR 0.91, 95% CI 0.77 to 1.07)[52]. This study 
included RCTs on critically ill patients with or without ARDS,  they found that conservative fluid strategy 
increased ventilator free days ventilator free days (MD 1.82 days; 95 % CI 0.53 to 3.10 days) and reduced ICU 
length of stay (MD - 1.88 days, 95 % CI -0.12 to -3.64 days), compared to a liberal fluid strategy.   There was 
no difference in harm, including renal failure between the two groups. The landmark trial on ARDS patients 
(FACTT) found a significant reduction in the duration of mechanical ventilation with conservative fluid 
strategy [109].  Furthermore, majority of patients with COVID-19 in the ICU are elderly, and may develop 
myocardial dysfunction which could limit their ability to handle large fluid volumes [46].  Because of the 
moderate benefit observed in other ARDS population, possible reduced cost by administering less fluids, and 
feasibility of the intervention, the panel issued a weak recommendation favoring conservative fluid strategy in 
patients with COVID-19 and ARDS. 
 
Recommendation:  
34. For mechanically ventilated adults with COVID-19 and moderate to severe ARDS, we suggest prone 





In a series of 81 patients with COVID-19, radiographic features progressed over the first 1 to 2 weeks 
following symptoms onset from predominant ground glass opacities to a mixed pattern of basilar 
predominant consolidation. This latter pattern may suggest a role for prone ventilation[110].  
Prone positioning theoretically makes ventilation more homogeneous by decreasing ventral alveolar 
distention and dorsal alveolar collapse [111]. This may reduce the difference between the dorsal and ventral 
transpulmonary pressures in addition to reducing lung compression [112] and improving perfusion [113].  
A recent study that described the clinical course of COVID-19 in the ICU showed the prone ventilation was 
used in 11.5% (6 out of 52 patients)[42], however, there are no studies to describe the clinical course of 
patients with COVID-19 who were ventilated in the prone position. 
A recent systematic review and meta-analysis of 9 RCTs (2,129 patients) showed that prone ventilation for at 
least 12 hours in patients with moderate to severe ARDS reduced mortality (5 RCTs; RR 0.74, 95% CI 0.56 to 
0.99), but had no effect on mortality in studies that used prone ventilation for <12 hours (3 RCTs; RR 1.03, 
95% CI 0.88 to1.20). On the other hand, prone ventilation increased the risks of pressure sores (RR 1.22, 
95% CI 1.06 to 1.41) and endotracheal tube obstruction (RR 1.76, 95% CI 1.24 to 2.50) [114]. Other 
systematic reviews reached similar conclusions [115-117]. 
We have moderate certainty that prone ventilation for more than 12 hours in patients with moderate to 
severe ARDS reduces mortality, but may increase the risk of pressure sores and endotracheal tube 
obstruction. Healthcare workers proning patients with COVID-19 should be trained on the proper technique 
for proning and take infection control precautions in case of accidental endotracheal tube disconnection from 
the ventilator. Proning itself is not associated with significant cost, and we believe that it may provide 
significant benefit. Further, proning can be implemented in low and middle income settings, and effort 




A protocol for proning should be used at each institution, based on the available resources and level of 
training. If prone ventilation is used, healthcare workers should be aware of complications such as pressure 
sores, vascular line and endotracheal tube displacement, facial edema, transient hemodynamic instability, 
corneal abrasions, brachial plexus injury, hemodialysis vascular access flow issues.  
In addition, clinicians should be familiar with absolute contraindications for prone ventilation such as 
unstable spine, open abdomen or open chest (i.e. surgery or trauma). Enteral nutrition via nasogastric or 
nasoduodenal tube can be continued during proning [118, 119].  
 
Recommendations: 
35. For mechanically ventilated adults with COVID-19 and moderate to severe ARDS: 
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35.1. We suggest using as needed intermittent boluses of neuromuscular blocking agents 
(NMBA), over a continuous NMBA infusion, to facilitate protective lung ventilation 
(weak recommendation, low quality evidence). 
 
35.2. In case of persistent ventilator dyssynchrony, requirement of ongoing deep sedation, 
prone ventilation, or persistently high plateau pressures; we suggest using a continuous 
NMBA infusion for up to 48 hours (weak recommendation, low quality evidence). 
 
Rationale: 
Several professional societies issued recommendations on the use of NMBAs in ARDS [100, 120-123]. Most 
issued recommendations favouring the use of an NMBA infusion in patients with moderate to severe ARDS; 
these recommendations were mostly based on the pooled estimates from 3 RCTs (431 patients) showing a 
reduction in 90-day mortality with an NMBA infusion compared to no NMBA infusion [124]. However, the 
results of the Re-evaluation of Systemic Early Neuromuscular Blockade (ROSE) trial challenged the results of 
previous trials. The ROSE trial investigators randomized 1,006 patients with moderate or severe ARDS to 
receive either an infusion of NMBA for 48 hours or intermittent NMBA boluses on an as needed basis [125]. 
The ROSE trial showed that a continuous infusion of cisatracurium did not improve any patient important 
outcomes.  
Due to differences in design between the ROSE trial and preceding trials, we did not perform meta-analysis 
for mortality outcome, although the pooled estimate for barotrauma was in favour of continuous NMBA 
infusion (RR 0.55, 95% CI 0.35 to 0.85). The panel suggest that a continuous NMBA infusion should be 
reserved for patients who have an indication for ongoing paralysis in which intermittent dosing may not 
suffice, such as patients with persistent ventilator dyssynchrony, requirement of ongoing deep sedation, prone 
ventilation, or persistently high plateau pressures. The effect of NMBAs on long term outcomes is unclear.     
 
Recommendations: 
36. For mechanically ventilated adults with COVID-19 ARDS, we recommend against the routine use of 
inhaled nitric oxide (strong recommendation, low quality evidence). 
 
37. For mechanically ventilated adults with COVID-19 severe ARDS and hypoxemia despite optimizing 
ventilation and other rescue strategies; we suggest a trial of inhaled pulmonary vasodilator as a rescue 
therapy, if no rapid improvement in oxygenation is observed, the treatment should be tapered off (weak 





No studies describe the use of pulmonary vasodilators in COVID-19 patients. A Cochrane review identified 
13 RCTs (1243 patients) on inhaled nitric oxide in ARDS; it showed no significant effect on mortality (RR 
1.04, 95% CI 0.9 to 1.19), and an increased risk of acute kidney injury (RR 1.59, 95% CI 1.17 to 2.16). Inhaled 
nitric oxide results in a transient improvement in oxygenation. In the subgroup of studies reporting 
PaO2/FiO2 (mm Hg) up to 24 hours after the intervention, there was a statistically significant difference in 
favour of inhaled nitric oxide, which was not present beyond 24 hours. No study assessed the use of inhaled 
nitric oxide as a “rescue” therapy [126]. Because of the possible harm from inhaled nitric oxide and lack of 
clear mortality benefit, the panel issued a strong recommendation against its routine use in patients with 
ARDS, however, because of improved oxygenation, a trial of inhaled nitric oxide as a “rescue” therapy, after 
trying other options, is reasonable if available. If inhaled nitric oxide is used without a good response in 
oxygenation, it should be tapered off to avoid rebound pulmonary vasoconstriction with prolonged use and 
abrupt discontinuation.   
No adequately powered RCTs evaluated inhaled prostacyclin such as ilioprost, therefore, we could not 
recommend against or for its use in severe ARDS.  
 
Recommendations: 
38. For mechanically ventilated adults with COVID-19 and hypoxemia despite optimizing ventilation, we 
suggest using recruitment maneuvers, over not using recruitment maneuvers (weak recommendation, 
low quality evidence). 
 
39. If recruitment maneuvers are used, we recommend against using staircase (incremental PEEP) 




No studies assessed the role of recruitment maneuvers (RMs) in patients with ARDS secondary to COVID-
19.  RMs aim to improve oxygenation by increasing transpulmonary pressure to open atelectatic alveoli [127].  
However, exposure to high levels of positive pressure may lead to barotrauma, as well as cause transient 
hypotension in already critically ill and unstable patients.   
We assessed 8 indirect RCTs assessing RMs in ARDS patients, including sepsis patients due to bacterial or 
viral pneumonia.  Varying strategies were used to help recruit atelectatic lungs, however two strategies were 
common in the 8 RCTs included in this meta-analysis.  Traditional RMs are described as prolonged 
inspiratory hold for a set duration of time on higher levels of CPAP; most commonly 35 to 40 cm H2O for 
40 seconds [93, 104, 128, 129].  Incremental PEEP titration RMs are described as incremental increases in 
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PEEP from 25 to 35 to 45 cm H20 for 1-2 minutes each [130-133]. 
 
In a systematic review and meta-analysis of 6 RCTs (1,423 patients), RMs reduced mortality and the use of 
rescue interventions, and improved oxygenation at 24 hours without increasing the risk of barotrauma [134].  
Similarly, we identified 8 RCTs (2,544) that reported on in-hospital mortality, RMs were not associated with 
reduced mortality (RR 0.90, 95% CI 0.78 to 1.04). However, subgroup analyses suggested that traditional 
RMs significantly reduced mortality (RR 0.85, 95%CI 0.75 to 0.97), while incremental PEEP titration RMs 
increased mortality (RR 1.06, 95% CI 0.97 to 1.17).  While the effects of RMs on oxygenation may be 
transient, the studies showed a significant improvement in oxygenation after 24 hours. Trials used different 
PEEP strategies in intervention and control arms; RMs are best combined with a higher PEEP strategy. 
Patients with severe ARDS and hypoxemia may benefit from traditional recruitment maneuvers along with 
higher levels of PEEP, but evidence specific to COVID-19 is needed.  Patients receiving RMs should be 




40. For mechanically ventilated adults with COVID-19 and refractory hypoxemia despite optimizing 
ventilation, use of rescue therapies and proning, we suggest using venovenous (VV) ECMO if available 
or referring the patient to an ECMO center (weak recommendation, low quality evidence). 
 
Remark: Due to the resource-intensive nature of ECMO, and the need for experienced centers and 
healthcare workers, and infrastructure, ECMO should only be considered in carefully selected patients with 
COVID-19 and severe ARDS.  
 
Rationale:  
There are no clinical trials of ECMO in COVID-19 patients. A recent report from China suggested that 
11.5% of COVID-19 in the ICU received ECMO [42], but the clinical course and the outcomes of these 
patients are not reported yet.  
 
The Ministry of Health in Saudi Arabia established an ECMO program during the MERS-CoV epidemic. In a 
retrospective cohort study of 35 patients with MERS-CoV and refractory hypoxemia, the group of patients 
who received VV ECMO had lower in-hospital mortality (65 vs.100%, P = 0.02) [135]. However, this cohort 




Only two RCTs have evaluated ECMO vs conventional mechanical ventilation in severe ARDS. Guidelines 
published in 2017 were unable to provide specific guidance on the use of ECMO, recommending further 
research [99]. Although, the most recent RCT (EOLIA) was stopped early for futility [136]; a re-analysis of 
the EOLIA using a Bayesian approach provided a more favorable interpretation of that trial, suggesting lower 
mortality with ECMO in severe ARDS [137]. A recent systematic review including two RCTs (429 patients) 
found a reduction in 60-day mortality with ECMO (RR 0.73, 95% CI 0.58 to 0.92), but the risk of major 
bleeding was higher with ECMO [138]. 
 
ECMO is resource-intensive and restricted to specialized centers, and it remains an extremely limited 
resource. Therefore, its use as a rescue therapy should be restricted to carefully selected patients [139]. Future 
studies describing the outcomes of COVID-19 patients on ECMO and the mechanism of death will advance 
our understanding and guide practice. 
 
IV. COVID-19 Therapy:  
 
In this section we will discuss possible treatment options for SARS CoV-2 and its complications, including 
antiviral agents, immunosuppressive agents, immunomodulators and other therapies.  
 
Cytokine Storm Syndrome 
Cytokine storm syndrome is a hyperinflammatory state that is characterized by fulminant multi-
organ failure and elevation of cytokine levels. A recent study from China showed that COVID-19 is 
associated with a cytokine elevation profile that is similar to secondary hemophagocytic 
lymphohistiocytosis (HLH) [44]. Some authors even suggest that we screen critically ill COVID-19 
patients for secondary HLH using the Hscore [140], and that in patients with high likelihood of 
HLH corticosteroids and other immunosuppressive agents can be used [141]. More evidence is 
needed before we can make recommendations on the treatment options for cytokine storm.  
 
Recommendations 
41. For mechanically ventilated adults with COVID-19 and respiratory failure (without ARDS), we suggest 
against the routine use of systemic corticosteroids (weak recommendation, low quality evidence). 
 
42. For mechanically ventilated adults with COVID-19 and ARDS, we suggest using systemic 
corticosteroids over not using corticosteroids (weak recommendation, low quality evidence). 
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Remark: The majority of our panel support a weak recommendation (i.e. suggestion) to use steroids in the 
sickest patients with COVID-19 and ARDS. However, because of the very low-quality evidence, some 
experts on the panel preferred not to issue a recommendation until higher quality direct-evidence is available. 
 
Rationale: 
There are no controlled clinical trials on the use of corticosteroids in COVID-19 patients or other 
coronaviruses. A published, but not peer-reviewed, report of 26 patients with severe COVID-19, report that 
the use of methylprednisolone at 1-2mg/kg/day for 5 to 7 days was associated with shorter duration of using 
supplemental oxygen (8.2 days vs. 13.5 days; P<0.001) and improvement in radiographic findings [142]. 
Although interesting, we judged these preliminary reports insufficient to formulate recommendations due to 
risk of confounding. Therefore, we used indirect evidence from community acquired pneumonia, ARDS, and 
other viral infections to inform our recommendation. 
 
There are several RCTs on the use of systemic corticosteroids for hospitalized patients with community 
acquired-pneumonia, mostly in non-ICU patients, where a proportion of these patients had sepsis or septic 
shock. A systematic review and meta-analysis of RCTs showed that using corticosteroids may reduce the need 
for mechanical ventilation (5 RCTs; 1060 patients; RR 0.45, 95% CI 0.26 to 0.79), ARDS (4 RCTs; 945 
patients; RR 0.24, 95% CI 0.10 to 0.56) and duration of hospitalization (6 RCTs; 1499 patients; MD -1.00 day, 
95% CI, -1.79 to -0.21), but increased the risk of hyperglycemia requiring treatment [143]. However, these 
trials included different population, the effect on mortality outcome was unclear, and they used different 
drugs and dosing regimens. In addition, there are some concerns about corticosteroid use in viral 
pneumonias. Therefore, the results may not be generalizable to COVID-19 population. 
 
There are many published observational studies on the use steroids in viral pneumonias (i.e. influenza virus, 
coronaviruses, and other), but they are prone to confounding, as sicker patients usually receive 
corticosteroids. We updated a recent Cochrane review on the use of corticosteroids in influenza[144] and 
searched for studies on other coronaviruses. We included a total of 15 cohort studies on influenza and 10 on 
coronaviruses. Our meta-analysis of adjusted ORs showed an association between corticosteroids use and 
increased mortality (OR 2.76, 95% CI 2.06 to 3.69), but the effect on patients with other coronaviruses was 
unclear (OR 0.83, 95% CI 0.32 to 2.17). Also, these studies are limited by significant heterogeneity. Among 
observational studies on the use of corticosteroids in ARDS caused by coronaviruses and general viral ARDS, 
there was significant heterogeneity (I2=82% and 77% respectively) and the summary statistic in both cases 




In ARDS, we updated a recent Cochrane review [145], and identified an additional RCT [146]. Overall, we 
included 7 RCTs enrolling 851 patients with ARDS. The use of corticosteroids reduced mortality (RR 0.75, 
95% CI 0.59 to 0.95) and duration of mechanical ventilation (MD -4.93 days, 95% CI -7.81 to -2.06). 
However, these trials were not focused on viral ARDS, therefore, limiting the generalizability of the results to 
COVID-19 patients.  In addition, we reviewed observational studies on corticosteroid use in viral ARDS, and 
identified 4 cohort studies. Although the point estimate showed increased mortality, the CI included 
substantial harm and benefit (OR 1.40, 95% CI 0.76 to 2.57). In a recent RCT (INTEREST trial) the use of 
recombinant interferon β1b (rIFN β1ba) did not reduce mortality in ARDS patients, but in the subgroup of 
patients receiving corticosteroids, rIFN β1ba use was associated with increased mortality (OR, 2.53, 95% CI 
1.12 to 5.72) [147]. Th only direct evidence comes from a retrospective cohort study of 201 patients with 
COVID-19 pneumonia. This study showed an association between use of corticosteroids and lower mortality 
in patients with COVID-19 and ARDS (HR 0.38, 95%CI 0.20 to 0.72). However, the estimate was not 
adjusted for confounding [148]. 
 
The effect of corticosteroids in COVID-19 patients with sepsis or septic shock may be different. Recent 
systematic reviews and meta-analyses of RCTs in sepsis showed small improvements in mortality and faster 
resolution of shock with corticosteroids use, compared to not using corticosteroids [63, 149, 150] (see the 
previous section on hemodynamic support). 
 
It is widely recognized that corticosteroids have a range of adverse effects. For viral pneumonia in the ICU, 
several studies showed increase of viral shedding with corticosteroid use [151-153], potentially indicating viral 
replication, but the clinical implication of increased viral shedding is uncertain. 
Considering the above, the panel issued a suggestion against the routine use of systemic corticosteroids for 
respiratory failure in COIVID-19, and a suggestion to use corticosteroids in the sicker population of COVID-




43. For mechanically ventilated patients with COVID-19 and respiratory failure, we suggest using empiric 




Remark: if the treating team initiates empiric antimicrobials, they should assess for de-escalation daily, and re-




There are no controlled clinical trials evaluating the use of empiric antimicrobials in COVID-19 patients or 
other coronaviruses. This recommendation is therefore based upon extrapolation of data from other viral 
pneumonias, particularly influenza [154]. Identifying bacterial co-infection or superinfection in patients with 
COVID-19 is challenging, the symptoms may be similar to those of the underlying viral infection. The 
diagnostic difficulty is reflected in high rates of intravenous antibiotics administered in Wuhan: 53% with 
non-severe disease and >90% of patients admitted to hospital or ICU [1, 42, 43]. There is limited data on the 
prevalence of bacterial superinfection in patients with COVID-19 as in larger case studies clinicians were 
often too overwhelmed to systematically obtain high-quality samples [1].  
 
In critically ill patients with MERS, 18% had bacterial co-infections and 5% viral co-infection [155]. Co-
infection with Staphylococcus aureus is common with influenza pneumonia and can be especially virulent [154]. 
Recent clinical practice guidelines recommend initiating empiric antibacterial therapy for adults with 
community-acquired pneumonia who test positive for influenza [154]. Data from critically ill patients 
demonstrate secondary infection in about 11% of patients, though numbers are small; isolated organisms 
included gram-negative organisms including K. pneumoniae, P. aeruganosa, and S. marcescens. Based upon this 
limited data it is difficult to determine patterns of superinfection, including risk of S. aureus infection, 
commonly seen in influenza.  
 
For patients with COVID-19 and hypoxic respiratory failure requiring mechanical ventilation, the panel 
suggest empiric antimicrobial treatment, on the basis that such infection is reasonably common in this 
population and may to lead to substantial increase in mortality, as in pandemic influenza [156-158]. Therefore, 
critically ill patients with suspected or confirmed COVID-19 should be treated with empiric antimicrobial 
therapy in accordance with the clinical syndrome (e.g., community-acquired or hospital-acquired pneumonia). 
Secondary infections occur in patients with COVID-19, but the incidence is unknown given the very limited 
data [159]. These infections should be treated according to clinical and microbiological data. 
 
Recommendation: 
44. For critically ill adults with COVID-19 who develop fever, we suggest using 






The majority of patients with COVID-19 develop fever during hospitalization (92% of those with severe 
disease), in the largest report from China, the median temperature across 1,099 patients was 38.3 °C (IQR 
37.8–38.9) [1].  Data from the general critically ill patients are available. We reviewed the literature and 
identified 12 RCTs (1,785 patients) that examined the effect of fever control in the critically ill population, 
excluding neurological indication for temperature control [160-171]; active temperature  management 
(pharmacologic or non-pharmacologic) did not reduce risk of death (RR 1.03, 95% CI 0.81 to 1.31),  ICU 
length of stay (MD -0.07 days, 95% CI -0.70 to 0.56), but it was effective in reducing body temperature (MD -
0.36 °C, 95% CI -0.42 lower to -0.29).  Given the safety of acetaminophen and lack of harm in the body of 
evidence, patient comfort with fever management maybe important. Therefore, we issued a suggestion for 
clinicians to consider using pharmacologic agents for controlling fever in the COIVD-19 patients. 
Recently, there is ongoing controversy about the use of non-steroidal anti-inflammatory drugs to treat fever 




45. For critically ill adults with COVID-19, we suggest against the routine use of standard intravenous 




The use of intravenous immunoglobulin has been reported in several series of COVID-19, but there is no 
efficacy data available [172]. In absence of adequate titers of neutralizing antibodies, standard intravenous 
immunoglobulin is unlikely to have a biologic effect in COVID-19. While IVIG may have 
immunomodulatory actions, its use can also be associated uncommonly with increased risk of serious adverse 
events including anaphylactic reactions, aseptic meningitis, renal failure, thromboembolism, hemolytic 
reactions, transfusion-related lung injury (TRALI), and other late reactions [173].  Preparations of anti-SARS-
CoV-2 polyclonal or monoclonal antibodies are being developed. However, data from recent trials on the use 
of antibody-based therapies (immune plasma, hyperimmune globulin, monoclonal antibody to 
hemagglutinin stalk)[173] in hospitalized seasonal influenza patients did not demonstrate improvement in 





46. In critically ill adults with COVID-19, we suggest against the routine use convalescent plasma (Weak 
recommendation, very low quality evidence). 
 
Rationale: 
Convalescent plasma obtained from previously recovered patients from COVID-19 has been suggested as a 
potential therapy by providing passive immunity from SARS-CoV2-specific antibodies [177]. Convalescent 
plasma has been used to treat several other viral infections, including those caused by SARS coronavirus, 
avian influenza A (H5N1) virus, and influenza A (H1N1) pdm09 virus [178-182]. A recent meta-analysis of 
observational studies using passive immunotherapy for treatment of severe acute respiratory infections of 
viral etiology suggests that convalescent plasma therapy was associated with reduction in mortality (OR 0.25, 
95% CI 0.14 to 0.45) [183]. During the current outbreak in China, convalescent plasma was used in some 
patients with COVID-19 [184]. However, the data on the efficacy and safety of convalescent plasma are 
limited, and the target for sufficient neutralizing antibody titers against SARS-CoV-2 is unknown. A study 
on MERS concluded that convalescent plasma might be feasible but was challenging due to a small pool of 
potential donors with sufficiently high antibody titers [185]. An RCT in patients with confirmed Ebola virus 
disease showed that convalescent plasma, with unknown levels of neutralizing antibodies, was not associated 
with improvement in survival [186]. Another RCT in patients with seasonal influenza of high-titer versus low-
titer anti-influenza immune plasma was terminated for futility because of the lack of effect on the primary 
outcome measured by a 6-point ordinal scale of clinical status on Day 7 [187]. Given the lack of convincing 
evidence from RCTs and the uncertainty surrounding the optimal preparation of the convalescent plasma and 




47. For critically ill adults with COVID-19: 
47.1.  we suggest against the routine use of lopinavir/ritonavir (weak recommendation, low 
quality evidence). 
47.2. There is insufficient evidence to issue a recommendation on the use of other 




The prolonged detection of SARS-CoV-2 RNA in the respiratory tract and sometimes other sites of seriously 
ill COVID-19 patients provides the rationale for administration of antiviral agents to reduce replication in 
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efforts to improve clinical outcomes  [45].  At present no direct-acting antivirals have been proven to inhibit 
replication or provide clinical benefit in COVID-19 or MERS patients.  
A considerable number of agents approved for other indications have been proposed for use, but the 
comments below address the most promising agents.  Several others are undergoing testing (e,g., arbidol 
[umifenovir], favipiravir, ribavirin, traditional Chinese medicines, inhaled interferons) alone or in 
combinations in one or more countries.   
 
Lopinavir is an antiretroviral protease inhibitors used in combination with ritonavir to ensure adequate 
lopinavir exposure for the treatment of human immunodeficiency virus (HIV) infection [188]. Because of 
in vitro activity against SARS-CoV, lopinavir/ritonavir was given in combination with high-dose oral 
ribavirin and tapering course of systemic corticosteroids in a cohort of 41 patients with SARS and found 
to be associated with significantly fewer adverse clinical outcomes (ARDS or death) compared to ribavirin 
alone used in 111 historical controls that received ribavirin and corticosteroids [189]. In a high-
throughput screening for antiviral compounds, lopinavir inhibited replication of MERS-CoV in vitro [190]. In 
an animal model of MERS-CoV infection, treatment with lopinavir/ritonavir or IFN-β1b was associated with 
virologic, histologic and clinical improvement compared to placebo [191]. Lopinavir/ritonavir in combination 
with interferon beta 1-b is being tested in an RCT on MERS-CoV patients [192] and this combination was 
considered the second candidate in the research prioritization list of therapeutic agents by WHO [193]. The 
drug has generally a good safety profile, but may have interactions with many drugs commonly used in 
critically ill patients (http://www.covid19-druginteractions.org/).  
A recent RCT compared the use of lopinavir/ritonavir to usual care in 199 hospitalized patients with 
COVID-19 in China [194]. In this trial, lopinavir/ritonavir did not significantly reduce 28-day mortality (RD, 
-5.8%; 95% CI, -17.3 to 5.7) or time to clinical improvement (MD 1.31 days, 95% CI 0.95 to 1.80). In 
addition, lopinavir/ritonavir was associated with more adverse events [194]. This trial is the only available 
direct evidence on the use of lopinavir/ritonavir in patients with COVID-19, however, it has several 
limitations. This trial was unblinded and it enrolled a small number of patients (n=199) with a small number 
of events (44 deaths in total), which limits our confidence in its results. Nevertheless, the routine use of 
lopinavir/ritonavir in critically ill patients is probably not warranted, and a weak recommendation against the 
routine use of lopinavir/ritonavir in critically ill COVID-19 patients is reasonable. 
Lopinavir/ritonavir is planned to be one of the arms of the WHO core treatment protocol for hospitalized 
patients with COVID-19, and in the REMAP-CAP (Randomized, Embedded, Multifactorial Adaptive 
Platform Trial for Community- Acquired Pneumonia) trial (NCT02735707), the results of ongoing trials will 




Remdesivir is the prodrug of an adenosine analogue, which incorporates into nascent viral RNA chains and 
results in pre-mature termination. It was considered the most promising drug in an informal consultation on 
research prioritization of candidate therapeutic agents by WHO [195]. Currently, there are published case 
reports but no published trials on the use of remdesivir in COVID-19. Remdesivir demonstrated effective 
inhibition of SARS-CoV-2, MERS-CoV, and SARS-CoV in vitro studies [196]. Furthermore, studies on 
animal models of MERS-CoV showed that it was more effective than control and superior to 
lopinavir/ritonavir combined with systemic IFN-β [197, 198]. Although intravenous remdesivir appears to 
adequately tolerated, a recent RCT showed that it was less effective than several antibody therapies in 
Ebola virus disease [199]. There are several ongoing RCTs that aim to examine the efficacy and safety of 
intravenous remdesivir for severe COVID-19 (clinicaltrials.gov NCT04257656) and for mild and moderate 
COVID-19 (clinicaltrials.gov NCT04252664). Another trial sponsored by the National Institute of Allergy 
and Infectious Diseases is recruiting patients in USA (clinicaltrials.gov NCT04280705). We will update our 




48. There is insufficient evidence to issue a recommendation on the use of recombinant rIFNs alone or 
in combination with antivirals in critically ill adults with COVID-19   
 
Rationale: 
Recombinant interferon often combined with ribavirin therapy has been used in patients with MERS and 
SARS [179, 200-202]. Different preparations of recombinant rIFNs (rIFN-α2a, rIFN-α2b, rIFN-β1a and 
rIFN-β1b) have shown activity against MERS-CoV in Vero and LLC-MK2 cells and in a rhesus macaques 
model of MERS-CoV infection [200, 201, 203]. The largest cohort of critically ill patients with MERS showed 
that rIFN-α2a, rIFN-α2b, rIFN-β1a and ribavirin were not associated with lower mortality (OR 1.03, 95% CI 
.73 to 1.44) or reduced viral clearance when adjusted for time-varying covariables [204]. The relative 
effectiveness of different interferons against SARS-CoV-2 is unknown at this point. 
In vitro data showed that rIFN-β had the strongest MERS-CoV inhibition among different rIFN preparations 
(rIFN-α2b, rIFN-γ, rIFN-universal, and rIFN-α2a, rIFN-β), at 41 times lower than the previously reported 
50% inhibitory concentration (IC50) of rIFN-α2b [203, 205]. An RCT is currently recruiting patients 
examining the effect of a combination of lopinavir /ritonavir and rIFN-β-1b on mortality of hospitalized 
patients with MERS [206]. Unpublished data indicate that IFN-β is inhibitory for SARS-C0V-2 in cell 





49. There is insufficient evidence to issue a recommendation on the use of chloroquine or 
hydroxychloroquine in critically ill adults with COVID-19   
 
Rationale: 
Chloroquine and its metabolite, hydroxychloroquine, are antimalarial agents, that have demonstrated to have 
antiviral effects on SARS-CoV and SARS-CoV-2 in vitro [207-209]. Prior studies found inhibitory effects of 
chloroquine for multiple RNA virus in vitro but RCTs in treatment of dengue and chikungunya virus infections and of 
influenza prophylaxis failed to demonstrate antiviral or clinical benefits [210]. One non-human primate model of 
chikungunya infection found that chloroquine’s immunomodulatory effects were associated with delayed immune 
responses, higher levels of viral replication, and worse illness [211]. A news briefing suggested that its use in more 
than 100 patients showed “that it was superior to the control in inhibiting the exacerbation of pneumonia, 
improving lung imaging findings, promoting a virus negative conversion, and shortening the disease course”, 
but data are not published yet [212]. A recent consensus document recommends chloroquine phosphate 500 
mg twice daily for minimum of 5 days; with dose modifications if severe gastrointestinal side effects occur 
[213]. Since chloroquine is not available in some countries, hydroxychloroquine is an alternative. A recent 
study in China explored various dosing regimens of chloroquine and hydroxychloroquine using 
physiologically-based pharmacokinetic models [209]. The study found hydroxychloroquine to be more potent 
than chloroquine in inhibiting SARS-CoV-2 in vitro. Based on these models hydroxychloroquine 400 mg 
twice daily for two doses followed by 200 mg twice daily for 4 days was recommended [209]. A recent 
systematic review found no published studies in COVID-19 patients [214]. Awaiting the results of ongoing 
trials, we were unable to issue a recommendation for or against chloroquine. 
 
Recommendation 
50. There is insufficient evidence to issue a recommendation on the use of tocilizumab in critically ill 
adults with COVID-19   
 
Rationale 
Tocilizumab is a humanized immunoglobulin that functions in the immune response and blocks IL-6 
receptor binding to IL-6 that has been approved for CRS and other inflammatory conditions related to IL-6 
related inflammation, such as rheumatoid arthritis and juvenile idiopathic arthritis [215-218]. Severely ill 
patients with COVID-19 may have an extreme immune response leading to severe respiratory failure. In such 
cases, inhibition of IL-6 may help attenuate the cytokine release syndrome by reducing cytokine 
concentrations and acute phase reactant production [219]. On-going trials of tocilizumab will help address the 
safety and efficacy of this therapy in COVID-19.  
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From the rheumatoid arthritis literature, a systematic review and meta-analysis of 6 RCTs (3 with 8/mg dose 
and 3 with 4mg/kg dose) showed an increased risk of adverse events compared control (OR 1.53, 95% CI 
1.26 to 1.86) and increased risk of infections (OR 1.30, 95% CI 1.07 to 1.58) [220]. Another systematic review 
and meta-analysis of RCTs on tocilizumab in rheumatoid arthritis found an increased risk of infectious 
respiratory adverse events (RR 1.53, 95% CI 1.04 to 2.25) [221]. Since we have no data on the safety or 
efficacy of tocilizumab in COVID-19, we were unable to issue a recommendation. 
 
Other agents 
Nafamostat, a synthetic serine protease inhibitor and a potent inhibitor of MERS CoV. Nitazoxanide is an 
antiprotozoal agent with an antiviral potential against several respiratory viruses including influenza, 
parainfluenza, respiratory syncytial virus and rhinovirus. In vitro study showed that both nafamostat and 
nitazoxanide inhibited SARS CoV-2 [196]. An RCT in patients with acute uncomplicated influenza 
demonstrated that the use of nitazoxanide reduced the duration of symptoms [222]. However, in hospitalized 
patients with severe acute respiratory infection in Mexico, showed that nitazoxanide was not superior to 
placebo [223]. 
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Table 1. Implications of different recommendations to key stakeholders 
Recommendation Meaning Implications to 
patients 
Implications to clinicians Implications to 
policymakers 
Strong 
recommendation or  
Best practice 
statement  




individuals in this 
situation would want 
the recommended 
intervention, and 
only a small 
proportion would 
not want it 
 
Most individuals should 
receive the recommended 
course of action 
Can be adapted as 
policy in most 
situations, including 











The majority of 
individuals in this 
situation would want 
the recommended 
intervention, but 
many would not 
Different choices are likely 
to be appropriate for 
different patients, and the 
recommendation should be 
tailored to the individual 
patient’s circumstances. 
Such as patients’, family’s, 
or substitute decision 
maker’s values and 
preferences 
 






Table 2. Recommendations and statements 
Recommendation Strength 
Infection Control and Testing: 
For healthcare workers performing aerosol-generating procedures* on patients with 
COVID-19 in the ICU, we recommend using fitted respirator masks (N95 
respirators, FFP2, or equivalent), as compared to surgical/medical masks, in addition 
to other personal protective equipment (i.e., gloves, gown, and eye protection such as a 
face shield or safety googles. 
Best practice 
statement 
We recommend performing aerosol-generating procedures on ICU patients with 
COVID-19 in a negative pressure room. 
Best practice 
statement 
For healthcare workers providing usual care for non-ventilated COVID-19 patients, we 
suggest using surgical/medical masks, as compared to respirator masks in addition to 
other personal protective equipment. 
Weak 
For healthcare workers who are performing non-aerosol-generating procedures on 
mechanically ventilated (closed circuit) patients with COVID-19, we suggest using 
surgical/medical masks as compared to respirator masks in addition to other personal 
protective equipment. 
Weak 
For healthcare workers performing endotracheal intubation on patients with COVID-
19, we suggest using video guided laryngoscopy, over direct laryngoscopy, if available. 
Weak 
For healthcare workers performing endotracheal intubation on patients with COVID-
19, we recommend endotracheal intubation is performed by healthcare worker 




For intubated and mechanically ventilated adults with suspicion of COVID-19, we 
suggest obtaining lower respiratory tract samples for diagnostic testing, over upper 
respiratory tract (nasopharyngeal or oropharyngeal) samples. 
Weak 
For lower respiratory samples, we suggest obtaining endotracheal aspirates, over 
bronchial wash or bronchoalveolar lavage samples. 
Weak 
Hemodynamics: 
For adults with COVID-19 and shock, we suggest using dynamic parameters, skin 
temperature, capillary refilling time, and/or lactate over static parameters to assess fluid 
responsiveness. 
Weak 
For the acute resuscitation of adults with COVID-19 and shock, we suggest using a 
conservative, over a liberal fluid strategy 
Weak 
For the acute resuscitation of adults with COVID-19 and shock, we recommend 
using crystalloids over colloids 
Weak 
For the acute resuscitation of adults with COVID-19 and shock, we suggest using 
buffered/balanced crystalloids over unbalanced crystalloids 
Weak 
For the acute resuscitation of adults with COVID-19 and shock, we recommend 
against using hydroxyethyl starches. 
Strong 
For the acute resuscitation of adults with COVID-19 and shock, we suggest against 
using gelatins. 
Weak 





For the acute resuscitation of adults with COVID-19 and shock, we suggest against 
the routine use of albumin for initial resuscitation. 
Weak 
For adults with COVID-19 and shock, we suggest using norepinephrine as the first-line 
vasoactive agent, over other agents 
Weak 
If norepinephrine is not available; for adults with COVID-19 and shock, we suggest 
using either vasopressin or epinephrine as the first-line vasoactive agent, over other 
vasoactive agents. 
Weak 
For adults with COVID-19 and shock, we recommend against using dopamine if 
norepinephrine is available. 
Strong 
For adults with COVID-19 and shock, we suggest adding vasopressin as a second-line 
agent, over titrating norepinephrine dose, if target mean arterial pressure (MAP) cannot 
be achieved by norepinephrine. 
Weak 
For adults with COVID-19 and shock, we suggest titrating vasoactive agents to target 
a MAP of 60-65 mmHg, over higher MAP targets. 
Weak 
For adults with COVID-19 and shock with evidence of cardiac dysfunction and 
persistent hypoperfusion despite fluid resuscitation and norepinephrine, we 
suggest adding dobutamine, over increasing norepinephrine dose. 
Weak 
For adults with COVID-19 and refractory shock, we suggest using low-dose 
corticosteroid therapy (“shock-reversal”), over no corticosteroid therapy  
Remark: typical corticosteroid regimen in septic shock is intravenous hydrocortisone 200 
mg per day either as an infusion or intermittent doses. 
Weak 
Ventilation 
For adults with COVID-19, we suggest starting supplemental oxygen if the peripheral 
oxygen saturation (SPO2) is < 92%, and recommend starting supplemental oxygen if 
SPO2 is < 90%. 
Weak 
Strong 
For adults with COVID-19 and acute hypoxemic respiratory failure on oxygen; we 
recommend that SPO2 be maintained no higher than 96%. 
Strong 
For adults with COVID-19 and acute hypoxemic respiratory failure despite 
conventional oxygen therapy, we suggest using HFNC over conventional oxygen 
therapy. 
Weak 
For adults with COVID-19 and acute hypoxemic respiratory failure, we suggest 
using HFNC over NIPPV 
Weak 
For adults with COVID-19 and acute hypoxemic respiratory failure, if HFNC is not 
available and no emergent indication for endotracheal intubation; we suggest a trial of 
NIPPV with close monitoring and short interval assessment for worsening of respiratory 
failure. 
Weak 
We were not able to make a recommendation regarding the use of helmet NIPPV 
compared to mask NIPPV, it is an option, but we are not certain about its safety or 
efficacy in COVID-19  
No 
recommendation 
For adults with COVID-19 receiving NIPPV or HFNC, we recommend close 
monitoring for worsening of respiratory status and early intubation in a controlled setting 
if worsening occurs. 
Best practice 
statement 
For mechanically ventilated adults with COVID-19 and ARDS, we recommend using 
low tidal volume (Vt) ventilation (Vt 4-8 mL/kg of predicted body weight), over higher 




For mechanically ventilated adults with COVID-19 and ARDS, we recommend 
targeting plateau pressures (Pplat) of < 30 cm H2O (strong recommendation, moderate 
quality evidence). 
Strong 
For mechanically ventilated adults with COVID-19 and moderate to severe ARDS, we 
suggest using a higher PEEP strategy, over lower PEEP strategy 
Strong 
For mechanically ventilated adults with COVID-19 and ARDS, we suggest using a 
conservative fluid strategy over a liberal fluid strategy. 
Weak 
For mechanically ventilated adults with COVID-19 and moderate to severe ARDS, we 
suggest prone ventilation for 12 to 16 hours, over no prone ventilation. 
Weak 
For mechanically ventilated adults with COVID-19 and moderate to severe ARDS, we 
suggest using as needed intermittent boluses of neuromuscular blocking agents 
(NMBA), over a continuous NMBA infusion, to facilitate protective lung ventilation. 
Weak 
In case of persistent ventilator dyssynchrony, requirement of ongoing deep sedation, 
prone ventilation, or persistently high plateau pressures; we suggest using a continuous 
NMBA infusion for up to 48 hours. 
Weak 
For mechanically ventilated adults with COVID-19 ARDS, we recommend against the 
routine use of inhaled nitric oxide. 
Weak 
For mechanically ventilated adults with COVID-19 severe ARDS and hypoxemia despite 
optimizing ventilation and other rescue strategies; we suggest a trial of inhaled 
pulmonary vasodilator as a rescue therapy, if no rapid improvement in oxygenation is 
observed, the treatment should be tapered off. 
Weak 
For mechanically ventilated adults with COVID-19 and hypoxemia despite optimizing 
ventilation, we suggest using recruitment maneuvers, over not using recruitment 
maneuvers. 
Weak 
If recruitment maneuvers are used, we recommend against using staircase (incremental 
PEEP) recruitment maneuvers. 
Strong 
For mechanically ventilated adults with COVID-19 and refractory hypoxemia despite 
optimizing ventilation, use of rescue therapies and proning, we suggest using 
venovenous (VV) ECMO if available or referring the patient to an ECMO center. 
Remark: Due to the resource-intensive nature of ECMO, and the need for experienced 
centers and healthcare workers, and infrastructure, ECMO should only be considered in 
carefully selected patients with COVID-19 and severe ARDS.  
Weak 
Therapy 
For mechanically ventilated adults with COVID-19 and respiratory failure (without 
ARDS), we suggest against the routine use of systemic corticosteroids 
Weak 
For mechanically ventilated adults with COVID-19 and ARDS, we suggest using 
systemic corticosteroids over not using corticosteroids. 
Remark: The majority of our panel support a weak recommendation (i.e. suggestion) to 
use steroids in the sickest patients with COVID-19 and ARDS. However, because of the 
very low quality evidence, some experts on the panel preferred not to issue a 
recommendation until higher quality direct-evidence is available. 
Weak 
For mechanically ventilated patients with COVID-19 and respiratory failure, we suggest 
using empiric antimicrobials/antibacterial agents, compared to no antimicrobials. 
Remark: if the treating team initiates empiric antimicrobials, they should assess for de-
escalation daily, and re-evaluate the duration of therapy and spectrum of coverage based 





For critically ill adults with COVID-19 who develop fever, we suggest using 
acetaminophen/paracetamol for temperature control, over no treatment. 
Weak 
For critically ill adults with COVID-19, we suggest against the routine use of standard 
intravenous immunoglobulins 
Weak 
In critically ill adults with COVID-19, we suggest against the routine use convalescent 
plasma. 
Weak 
For critically ill adults with COVID-19, we suggest against the routine use of 
lopinavir/ritonavir 
Weak 
There is insufficient evidence to issue a recommendation on the use of specific 
antiviral agents in critically ill adults with COVID-19. 
No 
recommendation 
There is insufficient evidence to issue a recommendation on the use of recombinant 
rIFNs alone or in combination with antivirals in critically ill adults with COVID-19. 
No 
recommendation 
There is insufficient evidence to issue a recommendation on the use of chloroquine 
or hydroxychloroquine in critically ill adults with COVID-19. 
No 
recommendation 
There is insufficient evidence to issue a recommendation on the use of tocilizumab 






Table 3. Epidemiological characteristics in recent COVID-19 reports. 
 




Shock NIPPV Invasive  
MV 
CFR 
Huang et al. [44] 41 32% 12% 7% 24% 5% 15% 
Chen et al. [65] 99 23% - 4% 13% 4% 11% 
Wang et al.[43] 138 26% 7% 9% 11% 12% - 
Guan et al.[1] 1099 - - 1% 5.1% 2.3% 1% 
Yang et al.[42] 52 100% 23% 35% 55.8% 42.3% 62% 
Zhou et al.[45] 191 26% 17% 20% 14% 17% 28% 






1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, 
Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng 
YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye 
CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for C, (2020) Clinical 
Characteristics of Coronavirus Disease 2019 in China. N Engl J Med  
2. European Centre for Disease Prevention and Control (2020, March 4) Situation update worldwide, 4 
March 2020. In: Editor (ed)^(eds) Book Situation update worldwide, 4 March 2020. City, pp.  
3. Alhazzani W, Lewis K, Jaeschke R, Rochwerg B, Moller MH, Evans L, Wilson KC, Patel S, 
Coopersmith CM, Cecconi M, Guyatt G, Akl EA, (2018) Conflicts of interest disclosure forms and 
management in critical care clinical practice guidelines. Intensive Care Med 44: 1691-1698 
4. Vandvik PO, Alhazzani W, Moller MH, (2018) Understanding conflicts of interest. Intensive Care 
Med 44: 1738-1740 
5. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter 
Y, Schunemann HJ, (2011) GRADE guidelines: 2. Framing the question and deciding on important 
outcomes. J Clin Epidemiol 64: 395-400 
6. Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M, Cook DJ, Guyatt GH, 
(2013) Addressing dichotomous data for participants excluded from trial analysis: a guide for 
systematic reviewers. PLoS One 8: e57132 
7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, 
Group GW, (2008) GRADE: an emerging consensus on rating quality of evidence and strength of 
recommendations. BMJ 336: 924-926 
8. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, 
Meerpohl J, Norris S, Guyatt GH, (2011) GRADE guidelines: 3. Rating the quality of evidence. J 
Clin Epidemiol 64: 401-406 
9. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post 
PN, Kunz R, Brozek J, Vist G, Rind D, Akl EA, Schunemann HJ, (2013) GRADE guidelines: 14. 
Going from evidence to recommendations: the significance and presentation of recommendations. J 
Clin Epidemiol 66: 719-725 
10. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, Brozek J, Norris S, Meerpohl J, 
Djulbegovic B, Alonso-Coello P, Post PN, Busse JW, Glasziou P, Christensen R, Schunemann HJ, 
(2013) GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin 
Epidemiol 66: 158-172 
11. Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, 
Brignardello-Petersen R, Neumann I, Falavigna M, Alhazzani W, Santesso N, Zhang Y, Meerpohl JJ, 
Morgan RL, Rochwerg B, Darzi A, Rojas MX, Carrasco-Labra A, Adi Y, AlRayees Z, Riva J, Bollig 
C, Moore A, Yepes-Nunez JJ, Cuello C, Waziry R, Akl EA, (2017) GRADE Evidence to Decision 
(EtD) frameworks for adoption, adaptation, and de novo development of trustworthy 
recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol 81: 101-110 
12. Wu Z, McGoogan JM, (2020) Characteristics of and Important Lessons From the Coronavirus 
Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the 
Chinese Center for Disease Control and Prevention. JAMA  
13. Livingston E, Bucher K, (2020) Coronavirus Disease 2019 (COVID-19) in Italy. JAMA  
14. Milton DK, Fabian MP, Cowling BJ, Grantham ML, McDevitt JJ, (2013) Influenza virus aerosols in 
human exhaled breath: particle size, culturability, and effect of surgical masks. PLoS Pathog 9: 
e1003205 
15. Twu SJ, Chen TJ, Chen CJ, Olsen SJ, Lee LT, Fisk T, Hsu KH, Chang SC, Chen KT, Chiang IH, Wu 
YC, Wu JS, Dowell SF, (2003) Control measures for severe acute respiratory syndrome (SARS) in 
Taiwan. Emerg Infect Dis 9: 718-720 
16. World Health Organization (2020, March 14) Clinical management of severe acute respiratory 
infection (sari) when covid-19 disease is suspected. In: Editor (ed)^(eds) Book Clinical management 
of severe acute respiratory infection (sari) when covid-19 disease is suspected. City, pp.  
 
 51 
17. Cabrini L, Landoni G, Zangrillo A, (2020) Minimise nosocomial spread of 2019-nCoV when treating 
acute respiratory failure. Lancet 395: 685 
18. Yam LY, Chen RC, Zhong NS, (2003) SARS: ventilatory and intensive care. Respirology 8 Suppl: 
S31-35 
19. Qian H, Li Y, Sun H, Nielsen PV, Huang X, Zheng X, (2010) Particle removal efficiency of the 
portable HEPA air cleaner in a simulated hospital ward. Building Simulation 3: 215-224 
20. Smith JD, MacDougall CC, Johnstone J, Copes RA, Schwartz B, Garber GE, (2016) Effectiveness of 
N95 respirators versus surgical masks in protecting health care workers from acute respiratory 
infection: a systematic review and meta-analysis. CMAJ 188: 567-574 
21. Radonovich LJ, Jr., Simberkoff MS, Bessesen MT, Brown AC, Cummings DAT, Gaydos CA, Los 
JG, Krosche AE, Gibert CL, Gorse GJ, Nyquist AC, Reich NG, Rodriguez-Barradas MC, Price CS, 
Perl TM, Res Pi, (2019) N95 Respirators vs Medical Masks for Preventing Influenza Among Health 
Care Personnel: A Randomized Clinical Trial. JAMA 322: 824-833 
22. Loeb M, Dafoe N, Mahony J, John M, Sarabia A, Glavin V, Webby R, Smieja M, Earn DJ, Chong S, 
Webb A, Walter SD, (2009) Surgical mask vs N95 respirator for preventing influenza among health 
care workers: a randomized trial. JAMA 302: 1865-1871 
23. MacIntyre CR, Wang Q, Cauchemez S, Seale H, Dwyer DE, Yang P, Shi W, Gao Z, Pang X, Zhang 
Y, Wang X, Duan W, Rahman B, Ferguson N, (2011) A cluster randomized clinical trial comparing 
fit-tested and non-fit-tested N95 respirators to medical masks to prevent respiratory virus infection 
in health care workers. Influenza Other Respir Viruses 5: 170-179 
24. MacIntyre CR, Wang Q, Rahman B, Seale H, Ridda I, Gao Z, Yang P, Shi W, Pang X, Zhang Y, Moa 
A, Dwyer DE, (2014) Efficacy of face masks and respirators in preventing upper respiratory tract 
bacterial colonization and co-infection in hospital healthcare workers. Prev Med 62: 1-7 
25. MacIntyre CR, Wang Q, Seale H, Yang P, Shi W, Gao Z, Rahman B, Zhang Y, Wang X, Newall AT, 
Heywood A, Dwyer DE, (2013) A randomized clinical trial of three options for N95 respirators and 
medical masks in health workers. Am J Respir Crit Care Med 187: 960-966 
26. Long Y, Hu T, Liu L, Chen R, Guo Q, Yang L, Cheng Y, Huang J, Du L, (2020) Effectiveness of 
N95 respirators versus surgical masks against influenza: A systematic review and meta-analysis. J 
Evid Based Med  
27. Tuite AR, Fisman DN, (2020) Reporting, Epidemic Growth, and Reproduction Numbers for the 
2019 Novel Coronavirus (2019-nCoV) Epidemic. Ann Intern Med  
28. Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L, (2014) Estimates of the reproduction 
number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC 
Infect Dis 14: 480 
29. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J, (2012) Aerosol generating procedures and 
risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS 
One 7: e35797 
30. Lewis SR, Butler AR, Parker J, Cook TM, Schofield-Robinson OJ, Smith AF, (2017) 
Videolaryngoscopy versus direct laryngoscopy for adult patients requiring tracheal intubation: a 
Cochrane Systematic Review. Br J Anaesth 119: 369-383 
31. Lewis SR, Butler AR, Parker J, Cook TM, Smith AF, (2016) Videolaryngoscopy versus direct 
laryngoscopy for adult patients requiring tracheal intubation. Cochrane Database Syst Rev 11: 
CD011136 
32. Russell TM, Hormis A, Rotherham NHSFT, (2018) Should the Glidescope video laryngoscope be 
used first line for all oral intubations or only in those with a difficult airway? A review of current 
literature. J Perioper Pract 28: 322-333 
33. Center of Disease Control (2020, February 14) Interim Guidelines for Collecting, Handling, and 
Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 
(COVID-19). In: Editor (ed)^(eds) Book Interim Guidelines for Collecting, Handling, and Testing 
Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 
(COVID-19). City, pp.  
 
 52 
34. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B, Kinoshita R, 
Nishiura H, (2020) Incubation Period and Other Epidemiological Characteristics of 2019 Novel 
Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. 
J Clin Med 9 
35. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brunink S, 
Schneider J, Schmidt ML, Mulders D, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, 
Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG, 
Drosten C, (2020) Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro 
Surveill 25 
36. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, Ng DYM, Wan CKC, Yang P, Wang 
Q, Peiris M, Poon LLM, (2020) Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing 
an Outbreak of Pneumonia. Clin Chem  
37. Xie C, Jiang L, Huang G, Pu H, Gong B, Lin H, Ma S, Chen X, Long B, Si G, Yu H, Jiang L, Yang 
X, Shi Y, Yang Z, (2020) Comparison of different samples for 2019 novel coronavirus detection by 
nucleic acid amplification tests. Int J Infect Dis  
38. Yam WC, Chan KH, Poon LL, Guan Y, Yuen KY, Seto WH, Peiris JS, (2003) Evaluation of reverse 
transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a 
novel coronavirus. J Clin Microbiol 41: 4521-4524 
39. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L, (2020) Correlation of Chest CT 
and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. 
Radiology: 200642 
40. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, Li Q, Gu S, Xu T, Li Y, Lu B, Zhan Q, (2020) Co-
infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. Emerg Infect 
Dis 26 
41. Chan PK, To WK, Ng KC, Lam RK, Ng TK, Chan RC, Wu A, Yu WC, Lee N, Hui DS, Lai ST, 
Hon EK, Li CK, Sung JJ, Tam JS, (2004) Laboratory diagnosis of SARS. Emerg Infect Dis 10: 825-
831 
42. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, 
Zou X, Yuan S, Shang Y, (2020) Clinical course and outcomes of critically ill patients with SARS-
CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet 
Respir Med  
43. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, 
Wang X, Peng Z, (2020) Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel 
Coronavirus-Infected Pneumonia in Wuhan, China. JAMA  
44. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, 
Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, 
Jin Q, Wang J, Cao B, (2020) Clinical features of patients infected with 2019 novel coronavirus in 
Wuhan, China. Lancet 395: 497-506 
45. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, 
Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B, (2020) Clinical course and risk factors for mortality of 
adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet  
46. Ruan Q, Yang K, Wang W, Jiang L, Song J, (2020) Clinical predictors of mortality due to COVID-19 
based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med  
47. Bednarczyk JM, Fridfinnson JA, Kumar A, Blanchard L, Rabbani R, Bell D, Funk D, Turgeon AF, 
Abou-Setta AM, Zarychanski R, (2017) Incorporating Dynamic Assessment of Fluid Responsiveness 
Into Goal-Directed Therapy: A Systematic Review and Meta-Analysis. Crit Care Med 45: 1538-1545 
48. Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT, (2016) Will This 
Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids? JAMA 316: 1298-
1309 
49. Pan J, Peng M, Liao C, Hu X, Wang A, Li X, (2019) Relative efficacy and safety of early lactate 




50. Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, Friedman G, 
Castro R, Alegria L, Teboul JL, Cecconi M, Ferri G, Jibaja M, Pairumani R, Fernandez P, Barahona 
D, Granda-Luna V, Cavalcanti AB, Bakker J, The ASI, the Latin America Intensive Care N, 
Hernandez G, Ospina-Tascon G, Petri Damiani L, Estenssoro E, Dubin A, Hurtado J, Friedman G, 
Castro R, Alegria L, Teboul JL, Cecconi M, Cecconi M, Ferri G, Jibaja M, Pairumani R, Fernandez P, 
Barahona D, Cavalcanti AB, Bakker J, Hernandez G, Alegria L, Ferri G, Rodriguez N, Holger P, 
Soto N, Pozo M, Bakker J, Cook D, Vincent JL, Rhodes A, Kavanagh BP, Dellinger P, Rietdijk W, 
Carpio D, Pavez N, Henriquez E, Bravo S, Valenzuela ED, Vera M, Dreyse J, Oviedo V, Cid MA, 
Larroulet M, Petruska E, Sarabia C, Gallardo D, Sanchez JE, Gonzalez H, Arancibia JM, Munoz A, 
Ramirez G, Aravena F, Aquevedo A, Zambrano F, Bozinovic M, Valle F, Ramirez M, Rossel V, 
Munoz P, Ceballos C, Esveile C, Carmona C, Candia E, Mendoza D, Sanchez A, Ponce D, Ponce D, 
Lastra J, Nahuelpan B, Fasce F, Luengo C, Medel N, Cortes C, Campassi L, Rubatto P, Horna N, 
Furche M, Pendino JC, Bettini L, Lovesio C, Gonzalez MC, Rodruguez J, Canales H, Caminos F, 
Galletti C, Minoldo E, Aramburu MJ, Olmos D, Nin N, Tenzi J, Quiroga C, Lacuesta P, Gaudin A, 
Pais R, Silvestre A, Olivera G, Rieppi G, Berrutti D, Ochoa M, Cobos P, Vintimilla F, Ramirez V, 
Tobar M, Garcia F, Picoita F, Remache N, Granda V, Paredes F, Barzallo E, Garces P, Guerrero F, 
Salazar S, Torres G, Tana C, Calahorrano J, Solis F, Torres P, Herrera L, Ornes A, Perez V, Delgado 
G, Lopez A, Espinosa E, Moreira J, Salcedo B, Villacres I, Suing J, Lopez M, Gomez L, Toctaquiza 
G, Cadena Zapata M, Orazabal MA, Pardo Espejo R, Jimenez J, Calderon A, Paredes G, Barberan 
JL, Moya T, Atehortua H, Sabogal R, Ortiz G, Lara A, Sanchez F, Hernan Portilla A, Davila H, Mora 
JA, Calderon LE, Alvarez I, Escobar E, Bejarano A, Bustamante LA, Aldana JL, (2019) Effect of a 
Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day 
Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical 
Trial. JAMA 321: 654-664 
51. Meyhoff TS, Moller MH, Hjortrup PB, Cronhjort M, Perner A, Wetterslev J, (2020) Lower versus 
higher fluid volumes during initial management of sepsis - a systematic review with meta-analysis and 
trial sequential analysis. Chest  
52. Silversides JA, Major E, Ferguson AJ, Mann EE, McAuley DF, Marshall JC, Blackwood B, Fan E, 
(2017) Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory 
distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-
analysis. Intensive Care Med 43: 155-170 
53. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, Nyeko R, Mtove G, 
Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell EC, Levin M, Babiker 
AG, Gibb DM, Group FT, (2011) Mortality after fluid bolus in African children with severe 
infection. N Engl J Med 364: 2483-2495 
54. Lewis SR, Pritchard MW, Evans DJ, Butler AR, Alderson P, Smith AF, Roberts I, (2018) Colloids 
versus crystalloids for fluid resuscitation in critically ill people. Cochrane Database Syst Rev 8: 
CD000567 
55. Antequera Martin AM, Barea Mendoza JA, Muriel A, Saez I, Chico-Fernandez M, Estrada-Lorenzo 
JM, Plana MN, (2019) Buffered solutions versus 0.9% saline for resuscitation in critically ill adults 
and children. Cochrane Database Syst Rev 7: CD012247 
56. Moller MH, Claudius C, Junttila E, Haney M, Oscarsson-Tibblin A, Haavind A, Perner A, (2016) 
Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with 
acute circulatory failure. Acta Anaesthesiol Scand 60: 1347-1366 
57. Gamper G, Havel C, Arrich J, Losert H, Pace NL, Mullner M, Herkner H, (2016) Vasopressors for 
hypotensive shock. Cochrane Database Syst Rev 2: CD003709 
58. Honarmand K, Um KJ, Belley-Cote EP, Alhazzani W, Farley C, Fernando SM, Fiest K, Grey D, 
Hajdini E, Herridge M, Hrymak C, Moller MH, Kanji S, Lamontagne F, Lauzier F, Mehta S, 
Paunovic B, Singal R, Tsang JL, Wynne C, Rochwerg B, (2020) Canadian Critical Care Society clinical 
practice guideline: The use of vasopressin and vasopressin analogues in critically ill adults with 
distributive shock. Can J Anaesth 67: 369-376 
 
 54 
59. McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, Lamontagne F, Healey JS, 
Whitlock RP, Belley-Cote EP, (2018) Association of Vasopressin Plus Catecholamine Vasopressors 
vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic 
Review and Meta-analysis. JAMA 319: 1889-1900 
60. Lamontagne F, Day AG, Meade MO, Cook DJ, Guyatt GH, Hylands M, Radermacher P, Chretien 
JM, Beaudoin N, Hebert P, D'Aragon F, Meziani F, Asfar P, (2018) Pooled analysis of higher versus 
lower blood pressure targets for vasopressor therapy septic and vasodilatory shock. Intensive Care 
Med 44: 12-21 
61. Lamontagne F, Richards-Belle A, Thomas K, Harrison DA, Sadique MZ, Grieve RD, Camsooksai J, 
Darnell R, Gordon AC, Henry D, Hudson N, Mason AJ, Saull M, Whitman C, Young JD, Rowan 
KM, Mouncey PR, trial i, (2020) Effect of Reduced Exposure to Vasopressors on 90-Day Mortality 
in Older Critically Ill Patients With Vasodilatory Hypotension: A Randomized Clinical Trial. JAMA  
62. Moller MH, Granholm A, Junttila E, Haney M, Oscarsson-Tibblin A, Haavind A, Laake JH, 
Wilkman E, Sverrisson KO, Perner A, (2018) Scandinavian SSAI clinical practice guideline on choice 
of inotropic agent for patients with acute circulatory failure. Acta Anaesthesiol Scand 62: 420-450 
63. Rygard SL, Butler E, Granholm A, Moller MH, Cohen J, Finfer S, Perner A, Myburgh J, Venkatesh 
B, Delaney A, (2018) Low-dose corticosteroids for adult patients with septic shock: a systematic 
review with meta-analysis and trial sequential analysis. Intensive Care Med 44: 1003-1016 
64. Lamontagne F, Rochwerg B, Lytvyn L, Guyatt GH, Moller MH, Annane D, Kho ME, Adhikari 
NKJ, Machado F, Vandvik PO, Dodek P, Leboeuf R, Briel M, Hashmi M, Camsooksai J, Shankar-
Hari M, Baraki MK, Fugate K, Chua S, Marti C, Cohen D, Botton E, Agoritsas T, Siemieniuk RAC, 
(2018) Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ 362: k3284 
65. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang 
X, Zhang L, (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus 
pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507-513 
66. van den Boom W, Hoy M, Sankaran J, Liu M, Chahed H, Feng M, See KC, (2020) The Search for 
Optimal Oxygen Saturation Targets in Critically Ill Patients: Observational Data From Large ICU 
Databases. Chest 157: 566-573 
67. Chu DK, Kim LH, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, Szczeklik W, Schunemann HJ, 
Neary JD, Alhazzani W, (2018) Mortality and morbidity in acutely ill adults treated with liberal versus 
conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet 391: 1693-1705 
68. Siemieniuk RAC, Chu DK, Kim LH, Guell-Rous MR, Alhazzani W, Soccal PM, Karanicolas PJ, 
Farhoumand PD, Siemieniuk JLK, Satia I, Irusen EM, Refaat MM, Mikita JS, Smith M, Cohen DN, 
Vandvik PO, Agoritsas T, Lytvyn L, Guyatt GH, (2018) Oxygen therapy for acutely ill medical 
patients: a clinical practice guideline. BMJ 363: k4169 
69. Investigators I-R, the A, New Zealand Intensive Care Society Clinical Trials G, Mackle D, Bellomo 
R, Bailey M, Beasley R, Deane A, Eastwood G, Finfer S, Freebairn R, King V, Linke N, Litton E, 
McArthur C, McGuinness S, Panwar R, Young P, (2019) Conservative Oxygen Therapy during 
Mechanical Ventilation in the ICU. N Engl J Med  
70. Barrot L, Asfar P, Mauny F, Winiszewski H, Montini F, Badie J, Quenot JP, Pili-Floury S, Bouhemad 
B, Louis G, Souweine B, Collange O, Pottecher J, Levy B, Puyraveau M, Vettoretti L, Constantin JM, 
Capellier G, Investigators L, Network RR, Investigators L, Network RR, (2020) Liberal or 
Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome. N Engl J Med 382: 999 
71. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, 
Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole 
X, Chevalier S, Herbland A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, 
Beduneau G, Deletage-Metreau C, Richard JC, Brochard L, Robert R, Group FS, Network R, (2015) 
High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 372: 
2185-2196 
72. Ni YN, Luo J, Yu H, Liu D, Liang BM, Liang ZA, (2018) The effect of high-flow nasal cannula in 
reducing the mortality and the rate of endotracheal intubation when used before mechanical 
 
 55 
ventilation compared with conventional oxygen therapy and noninvasive positive pressure 
ventilation. A systematic review and meta-analysis. Am J Emerg Med 36: 226-233 
73. Ou X, Hua Y, Liu J, Gong C, Zhao W, (2017) Effect of high-flow nasal cannula oxygen therapy in 
adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials. 
CMAJ 189: E260-E267 
74. Rochwerg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, Mekontso-Dessap A, Schreiber A, 
Azoulay E, Mercat A, Demoule A, Lemiale V, Pesenti A, Riviello ED, Mauri T, Mancebo J, Brochard 
L, Burns K, (2019) High flow nasal cannula compared with conventional oxygen therapy for acute 
hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med 45: 563-572 
75. Raboud J, Shigayeva A, McGeer A, Bontovics E, Chapman M, Gravel D, Henry B, Lapinsky S, Loeb 
M, McDonald LC, Ofner M, Paton S, Reynolds D, Scales D, Shen S, Simor A, Stewart T, 
Vearncombe M, Zoutman D, Green K, (2010) Risk factors for SARS transmission from patients 
requiring intubation: a multicentre investigation in Toronto, Canada. PLoS One 5: e10717 
76. Fowler RA, Guest CB, Lapinsky SE, Sibbald WJ, Louie M, Tang P, Simor AE, Stewart TE, (2004) 
Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation. Am 
J Respir Crit Care Med 169: 1198-1202 
77. Leung CCH, Joynt GM, Gomersall CD, Wong WT, Lee A, Ling L, Chan PKS, Lui PCW, Tsoi PCY, 
Ling CM, Hui M, (2019) Comparison of high-flow nasal cannula versus oxygen face mask for 
environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled 
crossover trial. J Hosp Infect 101: 84-87 
78. Cheung JC, Ho LT, Cheng JV, Cham EYK, Lam KN, (2020) Staff safety during emergency airway 
management for COVID-19 in Hong Kong. Lancet Respir Med  
79. Alraddadi BM, Qushmaq I, Al-Hameed FM, Mandourah Y, Almekhlafi GA, Jose J, Al-Omari A, 
Kharaba A, Almotairi A, Al Khatib K, Shalhoub S, Abdulmomen A, Mady A, Solaiman O, Al-Aithan 
AM, Al-Raddadi R, Ragab A, Balkhy HH, Al Harthy A, Sadat M, Tlayjeh H, Merson L, Hayden FG, 
Fowler RA, Arabi YM, Saudi Critical Care Trials G, (2019) Noninvasive ventilation in critically ill 
patients with the Middle East respiratory syndrome. Influenza Other Respir Viruses 13: 382-390 
80. Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, Hawa H, Alothman A, 
Khaldi A, Al Raiy B, (2014) Clinical course and outcomes of critically ill patients with Middle East 
respiratory syndrome coronavirus infection. Ann Intern Med 160: 389-397 
81. Zayed Y, Banifadel M, Barbarawi M, Kheiri B, Chahine A, Rashdan L, Haykal T, Samji V, Armstrong 
E, Bachuwa G, Al-Sanouri I, Seedahmed E, Hernandez DA, (2019) Noninvasive Oxygenation 
Strategies in Immunocompromised Patients With Acute Hypoxemic Respiratory Failure: A Pairwise 
and Network Meta-Analysis of Randomized Controlled Trials. J Intensive Care Med: 
885066619844713 
82. Xu XP, Zhang XC, Hu SL, Xu JY, Xie JF, Liu SQ, Liu L, Huang YZ, Guo FM, Yang Y, Qiu HB, 
(2017) Noninvasive Ventilation in Acute Hypoxemic Nonhypercapnic Respiratory Failure: A 
Systematic Review and Meta-Analysis. Crit Care Med 45: e727-e733 
83. Wang T, Zhang L, Luo K, He J, Ma Y, Li Z, Zhao N, Xu Q, Li Y, Yu X, (2016) Noninvasive versus 
invasive mechanical ventilation for immunocompromised patients with acute respiratory failure: a 
systematic review and meta-analysis. BMC Pulm Med 16: 129 
84. Esquinas AM, Egbert Pravinkumar S, Scala R, Gay P, Soroksky A, Girault C, Han F, Hui DS, 
Papadakos PJ, Ambrosino N, International NIVN, (2014) Noninvasive mechanical ventilation in 
high-risk pulmonary infections: a clinical review. Eur Respir Rev 23: 427-438 
85. Brochard L, Lefebvre JC, Cordioli RL, Akoumianaki E, Richard JC, (2014) Noninvasive ventilation 
for patients with hypoxemic acute respiratory failure. Semin Respir Crit Care Med 35: 492-500 
86. Slutsky AS, Ranieri VM, (2013) Ventilator-induced lung injury. N Engl J Med 369: 2126-2136 
87. Hui DSC, Zumla A, (2019) Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and 
Clinical Features. Infect Dis Clin North Am 33: 869-889 
88. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, Simonneau G, Benito S, 
Gasparetto A, Lemaire F, et al., (1995) Noninvasive ventilation for acute exacerbations of chronic 
obstructive pulmonary disease. N Engl J Med 333: 817-822 
 
 56 
89. Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, Navalesi PMOTSC, Antonelli M, 
Brozek J, Conti G, Ferrer M, Guntupalli K, Jaber S, Keenan S, Mancebo J, Mehta S, Raoof 
SMOTTF, (2017) Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute 
respiratory failure. Eur Respir J 50 
90. Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP, (2016) Effect of Noninvasive Ventilation 
Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute 
Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA 315: 2435-2441 
91. Hui DS, Chow BK, Lo T, Ng SS, Ko FW, Gin T, Chan MTV, (2015) Exhaled air dispersion during 
noninvasive ventilation via helmets and a total facemask. Chest 147: 1336-1343 
92. Walkey AJ, Goligher EC, Del Sorbo L, Hodgson CL, Adhikari NKJ, Wunsch H, Meade MO, Uleryk 
E, Hess D, Talmor DS, Thompson BT, Brower RG, Fan E, (2017) Low Tidal Volume versus Non-
Volume-Limited Strategies for Patients with Acute Respiratory Distress Syndrome. A Systematic 
Review and Meta-Analysis. Ann Am Thorac Soc 14: S271-S279 
93. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, 
Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR, (1998) Effect of a protective-
ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 338: 347-
354 
94. Villar J, Kacmarek RM, Perez-Mendez L, Aguirre-Jaime A, (2006) A high positive end-expiratory 
pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory 
distress syndrome: a randomized, controlled trial. Crit Care Med 34: 1311-1318 
95. Acute Respiratory Distress Syndrome N, Brower RG, Matthay MA, Morris A, Schoenfeld D, 
Thompson BT, Wheeler A, (2000) Ventilation with lower tidal volumes as compared with traditional 
tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 
1301-1308 
96. Brower RG, Shanholtz CB, Fessler HE, Shade DM, White P, Jr., Wiener CM, Teeter JG, Dodd-o 
JM, Almog Y, Piantadosi S, (1999) Prospective, randomized, controlled clinical trial comparing 
traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. 
Crit Care Med 27: 1492-1498 
97. Orme J, Jr., Romney JS, Hopkins RO, Pope D, Chan KJ, Thomsen G, Crapo RO, Weaver LK, 
(2003) Pulmonary function and health-related quality of life in survivors of acute respiratory distress 
syndrome. Am J Respir Crit Care Med 167: 690-694 
98. Wu G, Lu B, (1998) [The application of low tidal volume pressure-controlled ventilation in patients 
with acute respiratory distress syndrome]. Hunan Yi Ke Da Xue Xue Bao 23: 57-58 
99. Fan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, Adhikari NKJ, Amato MBP, 
Branson R, Brower RG, Ferguson ND, Gajic O, Gattinoni L, Hess D, Mancebo J, Meade MO, 
McAuley DF, Pesenti A, Ranieri VM, Rubenfeld GD, Rubin E, Seckel M, Slutsky AS, Talmor D, 
Thompson BT, Wunsch H, Uleryk E, Brozek J, Brochard LJ, American Thoracic Society ESoICM, 
Society of Critical Care M, (2017) An Official American Thoracic Society/European Society of 
Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical 
Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 
195: 1253-1263 
100. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, 
Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan 
GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, 
Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, 
Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, 
Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, 
Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der 
Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP, (2017) Surviving Sepsis Campaign: 




101. Thille AW, Rodriguez P, Cabello B, Lellouche F, Brochard L, (2006) Patient-ventilator asynchrony 
during assisted mechanical ventilation. Intensive Care Med 32: 1515-1522 
102. Yasuda H, Nishimura T, Kamo T, Sanui M, Nango E, Abe T, Takebayashi T, Lefor AK, Hashimoto 
S, (2017) Optimal plateau pressure for patients with acute respiratory distress syndrome: a protocol 
for a systematic review and meta-analysis with meta-regression. BMJ Open 7: e015091 
103. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, 
Thompson BT, National Heart L, Blood Institute ACTN, (2004) Higher versus lower positive end-
expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 351: 327-
336 
104. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou 
Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J, Skrobik Y, Ronco JJ, Stewart TE, Lung 
Open Ventilation Study I, (2008) Ventilation strategy using low tidal volumes, recruitment 
maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory 
distress syndrome: a randomized controlled trial. JAMA 299: 637-645 
105. Mercat A, Richard JC, Vielle B, Jaber S, Osman D, Diehl JL, Lefrant JY, Prat G, Richecoeur J, 
Nieszkowska A, Gervais C, Baudot J, Bouadma L, Brochard L, Expiratory Pressure Study G, (2008) 
Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress 
syndrome: a randomized controlled trial. JAMA 299: 646-655 
106. Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, Slutsky AS, Pullenayegum E, Zhou 
Q, Cook D, Brochard L, Richard JC, Lamontagne F, Bhatnagar N, Stewart TE, Guyatt G, (2010) 
Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute 
respiratory distress syndrome: systematic review and meta-analysis. JAMA 303: 865-873 
107. Guo L, Xie J, Huang Y, Pan C, Yang Y, Qiu H, Liu L, (2018) Higher PEEP improves outcomes in 
ARDS patients with clinically objective positive oxygenation response to PEEP: a systematic review 
and meta-analysis. BMC Anesthesiol 18: 172 
108. Walkey AJ, Del Sorbo L, Hodgson CL, Adhikari NKJ, Wunsch H, Meade MO, Uleryk E, Hess D, 
Talmor DS, Thompson BT, Brower RG, Fan E, (2017) Higher PEEP versus Lower PEEP Strategies 
for Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis. 
Ann Am Thorac Soc 14: S297-S303 
109. National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N, 
Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF, 
Jr., Hite RD, Harabin AL, (2006) Comparison of two fluid-management strategies in acute lung 
injury. N Engl J Med 354: 2564-2575 
110. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C, (2020) Radiological findings from 
81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis  
111. Cornejo RA, Diaz JC, Tobar EA, Bruhn AR, Ramos CA, Gonzalez RA, Repetto CA, Romero CM, 
Galvez LR, Llanos O, Arellano DH, Neira WR, Diaz GA, Zamorano AJ, Pereira GL, (2013) Effects 
of prone positioning on lung protection in patients with acute respiratory distress syndrome. Am J 
Respir Crit Care Med 188: 440-448 
112. Albert RK, Hubmayr RD, (2000) The prone position eliminates compression of the lungs by the 
heart. Am J Respir Crit Care Med 161: 1660-1665 
113. Nyren S, Radell P, Lindahl SG, Mure M, Petersson J, Larsson SA, Jacobsson H, Sanchez-Crespo A, 
(2010) Lung ventilation and perfusion in prone and supine postures with reference to anesthetized 
and mechanically ventilated healthy volunteers. Anesthesiology 112: 682-687 
114. Munshi L, Del Sorbo L, Adhikari NKJ, Hodgson CL, Wunsch H, Meade MO, Uleryk E, Mancebo J, 
Pesenti A, Ranieri VM, Fan E, (2017) Prone Position for Acute Respiratory Distress Syndrome. A 
Systematic Review and Meta-Analysis. Ann Am Thorac Soc 14: S280-S288 
115. Bloomfield R, Noble DW, Sudlow A, (2015) Prone position for acute respiratory failure in adults. 
Cochrane Database Syst Rev: CD008095 
116. Mora-Arteaga JA, Bernal-Ramirez OJ, Rodriguez SJ, (2015) The effects of prone position ventilation 
in patients with acute respiratory distress syndrome. A systematic review and metaanalysis. Med 
Intensiva 39: 359-372 
 
 58 
117. Lee JM, Bae W, Lee YJ, Cho YJ, (2014) The efficacy and safety of prone positional ventilation in 
acute respiratory distress syndrome: updated study-level meta-analysis of 11 randomized controlled 
trials. Crit Care Med 42: 1252-1262 
118. van der Voort PH, Zandstra DF, (2001) Enteral feeding in the critically ill: comparison between the 
supine and prone positions: a prospective crossover study in mechanically ventilated patients. Crit 
Care 5: 216-220 
119. Reintam Blaser A, Starkopf J, Alhazzani W, Berger MM, Casaer MP, Deane AM, Fruhwald S, 
Hiesmayr M, Ichai C, Jakob SM, Loudet CI, Malbrain ML, Montejo Gonzalez JC, Paugam-Burtz C, 
Poeze M, Preiser JC, Singer P, van Zanten AR, De Waele J, Wendon J, Wernerman J, Whitehouse T, 
Wilmer A, Oudemans-van Straaten HM, Function EWGoG, (2017) Early enteral nutrition in 
critically ill patients: ESICM clinical practice guidelines. Intensive Care Med 43: 380-398 
120. Murray MJ, DeBlock H, Erstad B, Gray A, Jacobi J, Jordan C, McGee W, McManus C, Meade M, 
Nix S, Patterson A, Sands MK, Pino R, Tescher A, Arbour R, Rochwerg B, Murray CF, Mehta S, 
(2016) Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill 
Patient. Crit Care Med 44: 2079-2103 
121. Griffiths M, Fan E, Baudouin SV, (2019) New UK guidelines for the management of adult patients 
with ARDS. Thorax 74: 931-933 
122. Claesson J, Freundlich M, Gunnarsson I, Laake JH, Moller MH, Vandvik PO, Varpula T, 
Aasmundstad TA, (2016) Scandinavian clinical practice guideline on fluid and drug therapy in adults 
with acute respiratory distress syndrome. Acta Anaesthesiol Scand 60: 697-709 
123. Papazian L, Aubron C, Brochard L, Chiche JD, Combes A, Dreyfuss D, Forel JM, Guerin C, Jaber S, 
Mekontso-Dessap A, Mercat A, Richard JC, Roux D, Vieillard-Baron A, Faure H, (2019) Formal 
guidelines: management of acute respiratory distress syndrome. Ann Intensive Care 9: 69 
124. Alhazzani W, Alshahrani M, Jaeschke R, Forel JM, Papazian L, Sevransky J, Meade MO, (2013) 
Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-
analysis of randomized controlled trials. Crit Care 17: R43 
125. National Heart L, Blood Institute PCTN, Moss M, Huang DT, Brower RG, Ferguson ND, Ginde 
AA, Gong MN, Grissom CK, Gundel S, Hayden D, Hite RD, Hou PC, Hough CL, Iwashyna TJ, 
Khan A, Liu KD, Talmor D, Thompson BT, Ulysse CA, Yealy DM, Angus DC, (2019) Early 
Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med 380: 1997-2008 
126. Gebistorf F, Karam O, Wetterslev J, Afshari A, (2016) Inhaled nitric oxide for acute respiratory 
distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev: CD002787 
127. Gattinoni L, Caironi P, Cressoni M, Chiumello D, Ranieri VM, Quintel M, Russo S, Patroniti N, 
Cornejo R, Bugedo G, (2006) Lung recruitment in patients with the acute respiratory distress 
syndrome. N Engl J Med 354: 1775-1786 
128. Kacmarek RM, Villar J, Sulemanji D, Montiel R, Ferrando C, Blanco J, Koh Y, Soler JA, Martinez D, 
Hernandez M, Tucci M, Borges JB, Lubillo S, Santos A, Araujo JB, Amato MB, Suarez-Sipmann F, 
Open Lung Approach N, (2016) Open Lung Approach for the Acute Respiratory Distress 
Syndrome: A Pilot, Randomized Controlled Trial. Crit Care Med 44: 32-42 
129. Xi XM, Jiang L, Zhu B, group RM, (2010) Clinical efficacy and safety of recruitment maneuver in 
patients with acute respiratory distress syndrome using low tidal volume ventilation: a multicenter 
randomized controlled clinical trial. Chin Med J (Engl) 123: 3100-3105 
130. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial I, 
Cavalcanti AB, Suzumura EA, Laranjeira LN, Paisani DM, Damiani LP, Guimaraes HP, Romano 
ER, Regenga MM, Taniguchi LNT, Teixeira C, Pinheiro de Oliveira R, Machado FR, Diaz-Quijano 
FA, Filho MSA, Maia IS, Caser EB, Filho WO, Borges MC, Martins PA, Matsui M, Ospina-Tascon 
GA, Giancursi TS, Giraldo-Ramirez ND, Vieira SRR, Assef M, Hasan MS, Szczeklik W, Rios F, 
Amato MBP, Berwanger O, Ribeiro de Carvalho CR, (2017) Effect of Lung Recruitment and 
Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With 
Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA 318: 1335-1345 
131. Hodgson CL, Tuxen DV, Davies AR, Bailey MJ, Higgins AM, Holland AE, Keating JL, Pilcher DV, 
Westbrook AJ, Cooper DJ, Nichol AD, (2011) A randomised controlled trial of an open lung 
 
 59 
strategy with staircase recruitment, titrated PEEP and targeted low airway pressures in patients with 
acute respiratory distress syndrome. Crit Care 15: R133 
132. Hodgson CL, Cooper DJ, Arabi Y, King V, Bersten A, Bihari S, Brickell K, Davies A, Fahey C, 
Fraser J, McGuinness S, Murray L, Parke R, Paul E, Tuxen D, Vallance S, Young M, Nichol A, 
(2019) Maximal Recruitment Open Lung Ventilation in Acute Respiratory Distress Syndrome 
(PHARLAP). A Phase II, Multicenter Randomized Controlled Clinical Trial. Am J Respir Crit Care 
Med 200: 1363-1372 
133. Huh JW, Jung H, Choi HS, Hong SB, Lim CM, Koh Y, (2009) Efficacy of positive end-expiratory 
pressure titration after the alveolar recruitment manoeuvre in patients with acute respiratory distress 
syndrome. Crit Care 13: R22 
134. Goligher EC, Hodgson CL, Adhikari NKJ, Meade MO, Wunsch H, Uleryk E, Gajic O, Amato MPB, 
Ferguson ND, Rubenfeld GD, Fan E, (2017) Lung Recruitment Maneuvers for Adult Patients with 
Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 
14: S304-S311 
135. Alshahrani MS, Sindi A, Alshamsi F, Al-Omari A, El Tahan M, Alahmadi B, Zein A, Khatani N, Al-
Hameed F, Alamri S, Abdelzaher M, Alghamdi A, Alfousan F, Tash A, Tashkandi W, Alraddadi R, 
Lewis K, Badawee M, Arabi YM, Fan E, Alhazzani W, (2018) Extracorporeal membrane oxygenation 
for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care 8: 3 
136. Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, Da Silva D, Zafrani L, Tirot 
P, Veber B, Maury E, Levy B, Cohen Y, Richard C, Kalfon P, Bouadma L, Mehdaoui H, Beduneau 
G, Lebreton G, Brochard L, Ferguson ND, Fan E, Slutsky AS, Brodie D, Mercat A, Eolia Trial 
Group R, Ecmonet, (2018) Extracorporeal Membrane Oxygenation for Severe Acute Respiratory 
Distress Syndrome. N Engl J Med 378: 1965-1975 
137. Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Juni P, Brodie D, Slutsky AS, 
Combes A, (2018) Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress 
Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a 
Randomized Clinical Trial. JAMA 320: 2251-2259 
138. Munshi L, Walkey A, Goligher E, Pham T, Uleryk EM, Fan E, (2019) Venovenous extracorporeal 
membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-
analysis. Lancet Respir Med 7: 163-172 
139. MacLaren G, Fisher D, Brodie D, (2020) Preparing for the Most Critically Ill Patients With COVID-
19: The Potential Role of Extracorporeal Membrane Oxygenation. JAMA  
140. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G, (2014) 
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic 
syndrome. Arthritis Rheumatol 66: 2613-2620 
141. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, COVID-19: consider 
cytokine storm syndromes and immunosuppression. The Lancet  
142. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, Dong N, Tong Q, (2020) Early, low-dose and 
short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: 
single-center experience from Wuhan, China. medRxiv: 2020.2003.2006.20032342 
143. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, Alexander PE, Fei Y, 
Vandvik PO, Loeb M, Guyatt GH, (2015) Corticosteroid Therapy for Patients Hospitalized With 
Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med 163: 
519-528 
144. Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS, (2019) Corticosteroids as 
adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2: CD010406 
145. Lewis SR, Pritchard MW, Thomas CM, Smith AF, (2019) Pharmacological agents for adults with 
acute respiratory distress syndrome. Cochrane Database Syst Rev 7: CD004477 
146. Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler JA, Aguilar G, Alba F, Gonzalez-
Higueras E, Conesa LA, Martin-Rodriguez C, Diaz-Dominguez FJ, Serna-Grande P, Rivas R, 
Ferreres J, Belda J, Capilla L, Tallet A, Anon JM, Fernandez RL, Gonzalez-Martin JM, 
 
 60 
dexamethasone in An, (2020) Dexamethasone treatment for the acute respiratory distress syndrome: 
a multicentre, randomised controlled trial. Lancet Respir Med 8: 267-276 
147. Ranieri VM, Pettila V, Karvonen MK, Jalkanen J, Nightingale P, Brealey D, Mancebo J, Ferrer R, 
Mercat A, Patroniti N, Quintel M, Vincent JL, Okkonen M, Meziani F, Bellani G, MacCallum N, 
Creteur J, Kluge S, Artigas-Raventos A, Maksimow M, Piippo I, Elima K, Jalkanen S, Jalkanen M, 
Bellingan G, Group IS, (2020) Effect of Intravenous Interferon beta-1a on Death and Days Free 
From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress 
Syndrome: A Randomized Clinical Trial. JAMA  
148. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, 
Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, 
Song Y, (2020) Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in 
Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med  
149. Rochwerg B, Oczkowski SJ, Siemieniuk RAC, Agoritsas T, Belley-Cote E, D'Aragon F, Duan E, 
English S, Gossack-Keenan K, Alghuroba M, Szczeklik W, Menon K, Alhazzani W, Sevransky J, 
Vandvik PO, Annane D, Guyatt G, (2018) Corticosteroids in Sepsis: An Updated Systematic Review 
and Meta-Analysis. Crit Care Med 46: 1411-1420 
150. Lian XJ, Huang DZ, Cao YS, Wei YX, Lian ZZ, Qin TH, He PC, Liu YH, Wang SH, (2019) 
Reevaluating the Role of Corticosteroids in Septic Shock: An Updated Meta-Analysis of Randomized 
Controlled Trials. Biomed Res Int 2019: 3175047 
151. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-
Omari A, Kharaba A, Almotairi A, Al Khatib K, Alraddadi B, Shalhoub S, Abdulmomen A, 
Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Balkhy HH, Al Harthy A, 
Deeb AM, Al Mutairi H, Al-Dawood A, Merson L, Hayden FG, Fowler RA, Saudi Critical Care Trial 
G, (2018) Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. 
Am J Respir Crit Care Med 197: 757-767 
152. Hui DS, (2018) Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle 
East Respiratory Syndrome Coronavirus Infection. Am J Respir Crit Care Med 197: 700-701 
153. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, Wong VW, Chan PK, Wong KT, Wong 
E, Cockram CS, Tam JS, Sung JJ, Lo YM, (2004) Effects of early corticosteroid treatment on plasma 
SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 31: 304-309 
154. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, 
Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, 
Alexander PE, Pavia AT, (2019) Clinical Practice Guidelines by the Infectious Diseases Society of 
America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak 
Management of Seasonal Influenzaa. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America 68: 895-902 
155. Arabi YM, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi AA, Alraddadi B, Shalhoub S, Almotairi 
A, Al Khatib K, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, 
Ragab A, Al Mekhlafi GA, Al Harthy A, Kharaba A, Ahmadi MA, Sadat M, Mutairi HA, Qasim EA, 
Jose J, Nasim M, Al-Dawood A, Merson L, Fowler R, Hayden FG, Balkhy HH, Saudi Critical Care 
Trial G, (2017) Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter 
Retrospective Cohort Study. Crit Care Med 45: 1683-1695 
156. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR, 3rd, Higgs E, Randolph AG, 
Smoot BE, Thompson BT, Network NA, (2012) Critical illness from 2009 pandemic influenza A 
virus and bacterial coinfection in the United States. Crit Care Med 40: 1487-1498 
157. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, Bhatnagar J, Sumner J, Liu L, Patel 
M, Batten B, Greer P, Jones T, Smith C, Bartlett J, Montague J, White E, Rollin D, Gao R, Seales C, 
Jost H, Metcalfe M, Goldsmith CS, Humphrey C, Schmitz A, Drew C, Paddock C, Uyeki TM, Zaki 
SR, (2010) 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the 
United States. Am J Pathol 177: 166-175 
158. McCullers JA, (2013) Do specific virus-bacteria pairings drive clinical outcomes of pneumonia? Clin 
Microbiol Infect 19: 113-118 
 
 61 
159. Alfonso J. Rodriguez-Morales, Jaime A. Cardona-Ospina, Estefanía Gutiérrez-Ocampo, Rhuvi 
Villamizar-Peña, Yeimer Holguin-Rivera, Juan Pablo Escalera-Antezana, Lucia Elena Alvarado-
Arnez, D. Katterine Bonilla-Aldana, Carlos Franco-Paredes, Andrés F. Henao-Martinez, Alberto 
Paniz-Mondolfi, Guillermo J. Lagos-Grisales, Eduardo Ramírez-Vallejo, Jose A. Suárez, Lysien I. 
Zambrano, Wilmer E. Villamil-Gómez, Graciela J. Balbin-Ramon, Ali A. Rabaan, Harapan Harapan, 
Kuldeep Dhama, Hiroshi Nishiura, Hiromitsu Kataoka, Tauseef Ahmad, Ranjit Sah, 
Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, 
Travel Medicine and Infectious Disease, 2020, 
https://www.sciencedirect.com/science/article/abs/pii/S1477893920300910?via%3Dihub 
160. Schulman CI, Namias N, Doherty J, Manning RJ, Li P, Elhaddad A, Lasko D, Amortegui J, Dy CJ, 
Dlugasch L, Baracco G, Cohn SM, (2005) The effect of antipyretic therapy upon outcomes in 
critically ill patients: a randomized, prospective study. Surg Infect (Larchmt) 6: 369-375 
161. Young P, Saxena M, Bellomo R, Freebairn R, Hammond N, van Haren F, Holliday M, Henderson S, 
Mackle D, McArthur C, McGuinness S, Myburgh J, Weatherall M, Webb S, Beasley R, Investigators 
H, Australian, New Zealand Intensive Care Society Clinical Trials G, (2015) Acetaminophen for 
Fever in Critically Ill Patients with Suspected Infection. N Engl J Med 373: 2215-2224 
162. Haupt MT, Jastremski MS, Clemmer TP, Metz CA, Goris GB, (1991) Effect of ibuprofen in patients 
with severe sepsis: a randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit 
Care Med 19: 1339-1347 
163. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright 
PE, Christman BW, Dupont WD, Higgins SB, Swindell BB, (1997) The effects of ibuprofen on the 
physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 
336: 912-918 
164. Gozzoli V, Schottker P, Suter PM, Ricou B, (2001) Is it worth treating fever in intensive care unit 
patients? Preliminary results from a randomized trial of the effect of external cooling. Arch Intern 
Med 161: 121-123 
165. Memis D, Karamanlioglu B, Turan A, Koyuncu O, Pamukcu Z, (2004) Effects of lornoxicam on the 
physiology of severe sepsis. Crit Care 8: R474-482 
166. Honarmand H, Abdollahi M, Ahmadi A, Javadi MR, Khoshayand MR, Tabeefar H, Mousavi S, 
Mahmoudi L, Radfar M, Najafi A, Mojtahedzadeh M, (2012) Randomized trial of the effect of 
intravenous paracetamol on inflammatory biomarkers and outcome in febrile critically ill adults. Daru 
20: 12 
167. Schortgen F, Clabault K, Katsahian S, Devaquet J, Mercat A, Deye N, Dellamonica J, Bouadma L, 
Cook F, Beji O, Brun-Buisson C, Lemaire F, Brochard L, (2012) Fever control using external cooling 
in septic shock: a randomized controlled trial. Am J Respir Crit Care Med 185: 1088-1095 
168. Niven DJ, Stelfox HT, Leger C, Kubes P, Laupland KB, (2013) Assessment of the safety and 
feasibility of administering antipyretic therapy in critically ill adults: a pilot randomized clinical trial. J 
Crit Care 28: 296-302 
169. Yang YL, Liu DW, Wang XT, Long Y, Zhou X, Chai WZ, (2013) Body temperature control in 
patients with refractory septic shock: too much may be harmful. Chin Med J (Engl) 126: 1809-1813 
170. Janz DR, Bastarache JA, Rice TW, Bernard GR, Warren MA, Wickersham N, Sills G, Oates JA, 
Roberts LJ, 2nd, Ware LB, Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis 
Study G, (2015) Randomized, placebo-controlled trial of acetaminophen for the reduction of 
oxidative injury in severe sepsis: the Acetaminophen for the Reduction of Oxidative Injury in Severe 
Sepsis trial. Crit Care Med 43: 534-541 
171. Schortgen F, Charles-Nelson A, Bouadma L, Bizouard G, Brochard L, Katsahian S, (2015) 
Respective impact of lowering body temperature and heart rate on mortality in septic shock: 
mediation analysis of a randomized trial. Intensive Care Med 41: 1800-1808 
172. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, Xu W, Zhang C, Yu J, Jiang B, Cao H, Li L, (2020) 
Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter 
Descriptive Study. Clinical Infectious Diseases  
 
 62 
173. Stiehm ER, (2013) Adverse effects of human immunoglobulin therapy. Transfus Med Rev 27: 171-
178 
174. Davey RT, Jr., Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, 
Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, 
Lundgren J, Beigel JH, Lane HC, Neaton JD, Davey RT, Fernández-Cruz E, Markowitz N, Pett S, 
Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska 
P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD, Butts J, Denning E, 
DuChene A, Krum E, Harrison M, Meger S, Peterson R, Quan K, Shaughnessy M, Thompson G, 
Vock D, Metcalf J, Dewar R, Rehman T, Natarajan V, McConnell R, Flowers E, Smith K, Hoover 
M, Coyle EM, Munroe D, Aagaard B, Pearson M, Cursley A, Webb H, Hudson F, Russell C, Sy A, 
Purvis C, Jackson B, Collaco-Moraes Y, Carey D, Robson R, Sánchez A, Finley E, Conwell D, Losso 
MH, Gambardella L, Abela C, Lopez P, Alonso H, Touloumi G, Gioukari V, Anagnostou O, 
Avihingsanon A, Pussadee K, Ubolyam S, Omotosho B, Solórzano C, Petersen T, Vysyaraju K, 
Rizza SA, Whitaker JA, Nahra R, Baxter J, Coburn P, Gardner EM, Scott JA, Faber L, Pastor E, 
Makohon L, MacArthur RA, Hillman LM, Farrough MJ, Polenakovik HM, Clark LA, Colon RJ, 
Kunisaki KM, DeConcini M, Johnson SA, Wolfe CR, Mkumba L, Carbonneau JY, Morris A, 
Fitzpatrick ME, Kessinger CJ, Salata RA, Arters KA, Tasi CM, Panos RJ, Lach LA, Glesby MJ, Ham 
KA, Hughes VG, Schooley RT, Crouch D, Muttera L, Novak RM, Bleasdale SC, Zuckerman AE, 
Manosuthi W, Thaonyen S, Chiewcharn T, Suwanpimolkul G, Gatechumpol S, Bunpasang S, Angus 
BJ, Anderson M, Morgan M, Minton J, Gkamaletsou MN, Hambleton J, Price DA, Llewelyn MJ, 
Sweetman J, Carbone J, Arribas JR, Montejano R, Lobo Beristain JL, Martinez IZ, Barberan J, 
Hernandez P, Dwyer DE, Kok J, Borges A, Brandt CT, Knudsen LS, Sypsas N, Constantinou C, 
Markogiannakis A, Zakynthinos S, Katsaounou P, Kalomenidis I, Mykietiuk A, Alzogaray MF, Obed 
M, Macias LM, Ebensrtejin J, Burgoa P, Nannini E, Lahitte M, Perez-Patrigeon S, Martínez-Orozco 
JA, Ramírez-Hinojosa JP, Anti-influenza hyperimmune intravenous immunoglobulin for adults with 
influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. The 
Lancet Respiratory Medicine  
175. Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC, (2019) Advances in 
respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. 
Antiviral research 167: 45-67 
176. Arabi YM, Fowler R, Hayden FG, (2020) Critical care management of adults with community-
acquired severe respiratory viral infection. Intensive Care Med 46: 315-328 
177. Casadevall A, Pirofski L-a, (2020) The convalescent sera option for containing COVID-19. The 
Journal of clinical investigation 130 
178. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu 
R, Lai KY, Lau CC, Liu SH, Chan KH, Lin CK, Yuen KY, (2013) Hyperimmune IV 
immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with 
severe 2009 influenza A(H1N1) infection. Chest 144: 464-473 
179. Stockman LJ, Bellamy R, Garner P, (2006) SARS: systematic review of treatment effects. PLoS Med 
3: e343 
180. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo 
CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan 
KH, Lin CK, Yuen KY, (2011) Convalescent plasma treatment reduced mortality in patients with 
severe pandemic influenza A (H1N1) 2009 virus infection. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 52: 447-456 
181. Luke TC, Kilbane EM, Jackson JL, Hoffman SL, (2006) Meta-analysis: convalescent blood products 
for Spanish influenza pneumonia: a future H5N1 treatment? Annals of internal medicine 145: 599-
609 
182. Kong LK, Zhou BP, (2006) Successful treatment of avian influenza with convalescent plasma. Hong 
Kong Med J 12: 489 
183. Mair-Jenkins J, Saavedra-Campos M, Baillie K, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, 
Nguyen-Van-Tam JS, Beck CR, (2014) The effectiveness of convalescent plasma and hyperimmune 
 
 63 
immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a 
systematic review and exploratory meta-analysis. The Journal of infectious diseases  
184. China puts 245 COVID-19 patients on convalescent plasma therapy. News release. Xinhua. February 
28, 2020. Accessed March 13, 2020. http://www.xinhuanet.com/english/2020-
02/28/c_138828177.htm. 
185. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, Al-
Omari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A, Shindo N, Al-Khairy K, Carson G, 
Taha Y, Sadat M, Alahmadi M, (2016) Feasibility of Using Convalescent Plasma Immunotherapy for 
MERS-CoV Infection, Saudi Arabia. Emerging infectious diseases 22: 1554-1561 
186. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, 
Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, 
Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, 
Haba N, Ebola-Tx C, (2016) Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. 
The New England journal of medicine 374: 33-42 
187. Beigel JH, Aga E, Elie-Turenne M-C, Cho J, Tebas P, Clark CL, Metcalf JP, Ozment C, Raviprakash 
K, Beeler J, Holley HP, Jr., Warner S, Chorley C, Lane HC, Hughes MD, Davey RT, Jr., Beigel JH, 
Aga E, Elie-Turenne M-C, Cho J, Tebas P, Clark CL, Metcalf JP, Ozment C, Raviprakash K, Beeler 
J, Holley HP, Jr., Warner S, Chorley C, Lane HC, Hughes MD, Davey RT, Barron M, Bastani A, 
Bauer P, Borkowsky W, Cairns C, Deville J, Elie M-C, Fichtenbaum C, Finberg R, Jain M, Kaufman 
D, Lin M, Lin J, Maves R, Morrow L, Nguyen M-H, Park P, Polk C, Randolph A, Rao S, Rubinson 
L, Schofield C, Shoham S, Stalets E, Stapleton RD, Anti-influenza immune plasma for the treatment 
of patients with severe influenza A: a randomised, double-blind, phase 3 trial. The Lancet Respiratory 
Medicine  
188. Huang X, Xu Y, Yang Q, Chen J, Zhang T, Li Z, Guo C, Chen H, Wu H, Li N, (2015) Efficacy and 
biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a 
meta-analysis of randomized controlled trials. Scientific reports 5: 8528 
189. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL, Wong CL, 
Guan Y, Peiris JS, Yuen KY, Group HUSS, (2004) Role of lopinavir/ritonavir in the treatment of 
SARS: initial virological and clinical findings. Thorax 59: 252-256 
190. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer 
TM, van den Hoogen BG, Neyts J, Snijder EJ, (2014) Screening of an FDA-approved compound 
library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus 
replication in cell culture. Antimicrob Agents Chemother 58: 4875-4884 
191. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou 
J, Chen H, Qin C, Yuen KY, (2015) Treatment With Lopinavir/Ritonavir or Interferon-beta1b 
Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common 
Marmoset. The Journal of infectious diseases 212: 1904-1913 
192. Arabi YM, Asiri AY, Assiri AM, Aziz Jokhdar HA, Alothman A, Balkhy HH, AlJohani S, Al Harbi S, 
Kojan S, Al Jeraisy M, Deeb AM, Memish ZA, Ghazal S, Al Faraj S, Al-Hameed F, AlSaedi A, 
Mandourah Y, Al Mekhlafi GA, Sherbeeni NM, Elzein FE, Almotairi A, Al Bshabshe A, Kharaba A, 
Jose J, Al Harthy A, Al Sulaiman M, Mady A, Fowler RA, Hayden FG, Al-Dawood A, Abdelzaher M, 
Bajhmom W, Hussein MA, and the Saudi Critical Care Trials g, (2020) Treatment of Middle East 
respiratory syndrome with a combination of lopinavir/ritonavir and interferon-beta1b (MIRACLE 
trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. 
Trials 21: 8 
193. World Health Organization Informal consultation on prioritization of candidate therapeutic agents 
for use in novel coronavirus 2019 infection. In: Editor (ed)^(eds) Book Informal consultation on 
prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection. City, pp.  
194. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, 
Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, 
Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong 
X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, 
 
 64 
Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, 
Zhang D, Wang C, (2020) A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-
19. New England Journal of Medicine  
195. World Health Organization. Informal consultation on prioritization of candidate therapeutic agents 
for use in novel coronavirus 2019 infection. Jan 24 2020. 
https://apps.who.int/iris/bitstream/handle/10665/330680/WHO-HEO-
RDBlueprint%28nCoV%29-2020.1-eng.pdf (accessed March 10 2020). 
196. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G, (2020) Remdesivir 
and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell 
research 30: 269-271 
197. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, 
Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric 
RS, (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and 
interferon beta against MERS-CoV. Nature communications 11: 222 
198. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H, 
(2020) Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of 
MERS-CoV infection. Proceedings of the National Academy of Sciences of the United States of 
America  
199. Mulangu S, Dodd LE, Davey RT, Jr., Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo 
M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane 
HC, Muyembe-Tamfum JJ, Group PW, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp 
B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage 
M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley 
L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, 
Holman W, Gettinger N, Vallee D, Nordwall J, Team PCS, (2019) A Randomized, Controlled Trial 
of Ebola Virus Disease Therapeutics. The New England journal of medicine 381: 2293-2303 
200. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H, (2013) Inhibition of novel 
beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Scientific reports 
3: 1686 
201. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker 
T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ, Feldmann H, (2013) Treatment 
with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. 
Nature medicine 19: 1313-1317 
202. Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA, (2013) Therapeutic options for 
Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic 
review of SARS-CoV therapy. International journal of infectious diseases : IJID : official publication 
of the International Society for Infectious Diseases 17: e792-798 
203. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG, Jr., Frieman MB, 
Holbrook MR, Jahrling PB, Hensley L, (2014) Interferon-beta and mycophenolic acid are potent 
inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. The Journal of 
general virology 95: 571-577 
204. Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, Jose J, Alraddadi B, 
Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Sindi AA, Mady A, Solaiman O, Al-Raddadi 
R, Maghrabi K, Ragab A, Al Mekhlafi GA, Balkhy HH, Al Harthy A, Kharaba A, Gramish JA, Al-
Aithan AM, Al-Dawood A, Merson L, Hayden FG, Fowler R, (2019) Ribavirin and Interferon 
Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter 
Observational Study. Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America  
205. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, 
Yuen KY, (2013) Broad-spectrum antivirals for the emerging Middle East respiratory syndrome 
coronavirus. The Journal of infection 67: 606-616 
 
 65 
206. Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, 
Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, 
Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, 
Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA, And the Mtg, (2018) Treatment of Middle 
East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b 
(MIRACLE trial): study protocol for a randomized controlled trial. Trials 19: 81 
207. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST, 
(2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2: 69 
208. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G, (2020) Remdesivir 
and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell 
Res  
209. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li 
H, Tan W, Liu D, (2020) In Vitro Antiviral Activity and Projection of Optimized Dosing Design of 
Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2). Clin Infect Dis  
210. Touret F, de Lamballerie X, (2020) Of chloroquine and COVID-19. Antiviral Res 177: 104762 
211. Roques P, Thiberville SD, Dupuis-Maguiraga L, Lum FM, Labadie K, Martinon F, Gras G, Lebon P, 
Ng LFP, de Lamballerie X, Le Grand R, (2018) Paradoxical Effect of Chloroquine Treatment in 
Enhancing Chikungunya Virus Infection. Viruses 10 
212. Gao J, Tian Z, Yang X, (2020) Breakthrough: Chloroquine phosphate has shown apparent efficacy in 
treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends  
213. multicenter collaboration group of Department of S, Technology of Guangdong P, Health 
Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, (2020) 
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. 
Zhonghua Jie He He Hu Xi Za Zhi 43: E019 
214. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S, (2020) A systematic review on the 
efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care  
215. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, 
Xavier RM, Calvo I, Nikishina I, Rubio-Perez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-
Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gamir ML, Martin A, 
Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology 
International Trials Organisation P, Pediatric Rheumatology Collaborative Study G, (2015) Efficacy 
and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results 
from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases 74: 
1110-1117 
216. Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, Mangan EK, 
Spindler A, Huizinga TWJ, van der Heijde D, investigators Es, (2018) Two years of sarilumab in 
patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and 
radiographic outcomes. Rheumatology (Oxford) 57: 1423-1431 
217. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, 
Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T, (2008) Efficacy and safety of tocilizumab in 
patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-
controlled, withdrawal phase III trial. Lancet 371: 998-1006 
218. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R, 
(2018) FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐
induced severe or life‐threatening cytokine release syndrome. The oncologist 23: 943 
219. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B, Ding J, Li F, 
(2020) Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically 




220. Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ, (2011) Risk of adverse events including 
serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature 
review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 50: 552-562 
221. Geng Z, Yu Y, Hu S, Dong L, Ye C, (2019) Tocilizumab and the risk of respiratory adverse events in 
patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled 
trials. Clinical and experimental rheumatology 37: 318-323 
222. Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, Bardin M, Rossignol JF, 
Group USNICS, (2014) Effect of nitazoxanide in adults and adolescents with acute uncomplicated 
influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. The Lancet Infectious 
diseases 14: 609-618 
223. Gamino-Arroyo AE, Guerrero ML, McCarthy S, Ramirez-Venegas A, Llamosas-Gallardo B, 
Galindo-Fraga A, Moreno-Espinosa S, Roldan-Aragon Y, Araujo-Melendez J, Hunsberger S, Ibarra-
Gonzalez V, Martinez-Lopez J, Garcia-Andrade LA, Kapushoc H, Holley HP, Jr., Smolskis MC, 
Ruiz-Palacios GM, Beigel JH, Mexico Emerging Infectious Diseases Clinical Research N, (2019) 
Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe 
Acute Respiratory Illness. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America  
 
